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ABSTRACT OF DISSERTATION

SPINAL KAPPA OPIOID RECEPTOR ACTIVITY INHIBITS ADENYLYL
CYCLASE-1 DEPENDENT MECHANISMS OF CHRONIC POSTOPERATIVE PAIN
Chronic postoperative pain impacts millions of individuals worldwide that undergo
a variety of surgical procedures. Opioids remain the mainstay analgesics of acute and
perioperative pain; however, prolonged opioid therapy may lead to life-threating adverse
effects, tolerance, dependence, and addiction. Therefore, unraveling the cellular
mechanisms that drive persistent pain states and opposing endogenous analgesia provided
by opioid receptor signaling, may lead to novel analgesics. Evidence suggests that tissue
injury leads to increased sensitization of the spinal cord nociceptive neurons which
increases susceptibility to chronic pain via an N-methyl-D-aspartate (NMDA) receptor
activation of calcium-sensitive adenylyl cyclase isoform 1 (AC1). This phenomenon,
named latent pain sensitization (LS), is mediated by a compensatory response of
endogenous inhibitory systems.
In this dissertation, we test the hypothesis that surgical insult promotes prolonged
activation of kappa opioid receptors (KOR) which mask LS via attenuation of pronociceptive AC1 signaling pathways in both male and female animals. We employed a
murine model of chronic postoperative pain that promotes LS in the spinal cord and closely
resembles the phenotypic features of postoperative pain in human subjects. When
behavioral signs of hyperalgesia resolved, we targeted spinal opioid receptor systems and
pronociceptive modulators with intrathecal delivery of selective pharmacological
antagonists and assessed behavioral signs of hyperalgesia and spinal nociceptive
sensitization. We propose that LS is kept in remission by a long-lasting compensatory
response of tonic endogenous KOR signaling that hinders a pronociceptive LS pathway
that includes not only AC1 but also two downstream targets: protein kinase A (PKA) and
exchange protein activated by cAMP (Epac1/2) - in a sex-dependent manner. Our results
propose new therapeutic targets for the management of persistent postoperative pain and
underscore the importance of tailoring sex-specific pain management strategies.

KEYWORDS: Postoperative pain, latent pain sensitization, kappa opioid receptor,
adenylyl cyclase -1, protein kinase A, exchange protein activated by cAMP.
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CHAPTER 1. Introduction and Overall Hypothesis

1.1 Introduction
Chronic pain is an emergent cause of morbidity and long-term disability worldwide.
With an estimated minimum 1/3 of the adult United States population suffering from
chronic pain, the costs in healthcare account for approximately $600 billion annually
(Medicine, 2011). In fact, 11.2% of Americans report moderate to severe daily pain (Nahin,
2015), and 4.8% of chronic pain patients exhibit high rates of disability, psychological and
cognitive impairment (Pitcher et al., 2018). The increased burden of chronic pain is
exacerbated by the fact that many patients are refractory to available pharmacological
interventions. For instance, almost 20% of patients with neuropathic pain are placed on
long-term opioid regimens as the ultimate resource to manage the pain severity, improve
their quality of life and functional impairment (Eriksen et al., 2006; Hoffman et al., 2017).
Among the chronic pain patients on prolonged opioid therapy, over 60% report having
initiated opioids following surgical procedures (Callinan et al., 2017). Long-term opioid
therapy, however, it is only moderately effective at best and can lead to not only lifethreatening adverse effects, but also analgesic tolerance, dependence, abuse liability and
paradoxical pain exacerbation (Eriksen et al., 2006). Therefore, there is an increased need
for multidisciplinary approaches and research leading to novel and efficacious non-opioid
treatment modalities for chronic pain.
One of the significant challenges in pain research is to understand the mechanisms
of chronic pain and its inhibition. There is a consensus that persistent pain states result
from maladaptive plasticity of a network of neurons in the CNS, including the dorsal horn
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of the spinal cord (Sessle, 2000; Latremoliere and Woolf, 2009; Sandkuhler and GruberSchoffnegger, 2012). Tissue injury or inflammation produce increased excitability of
nociceptive circuits that are driven by N-methyl-D-aspartate (NMDA) glutamatergic
receptor dependent activities in the central synapses and their downstream pathways
(Woolf, 2007; Zhuo, 2012). Thus, uncovering the cellular mechanisms that are involved in
pain-related plasticity is critical for developing more effective pharmacological
approaches.
It is well recognized that spinal nociceptive transmission is modulated by activation
of opioid receptors in the peripheral and central nervous system (CNS) upon coupling of
exogenous agonists or its endogenous ligands (Yaksh, 1987). We postulate that tissue
injury is followed by a period of long-lasting pain vulnerability entitled latent sensitization
(LS), in which sensitized spinal nociceptive pathways remain quiescent due to
compensatory activity of pain inhibitory systems in the dorsal horn (Solway et al., 2011;
Corder et al., 2013) that outlasts the resolution of the injury. Disruption of the inhibitory
systems due to subsequent exposure to an injury (Taylor and Corder, 2014; Pereira et al.,
2015b) or stressful events (Rivat et al., 2007; Marvizon et al., 2015) can trigger episodes
of hyperalgesia. The silent phase of LS can be unmasked upon administration of the nonselective antagonist/inverse agonist of opioid receptors-naltrexone or naloxone in rodents
(Campillo et al., 2011; Corder et al., 2013), and in a subpopulation of susceptible human
subjects (Pereira et al., 2015b). This phenomenon indicates a compensatory endogenous
opioid mechanism after injury, where mu opioid receptors (MOR) become constitutively
active (MORCA) to combat opposing processes of pain transduction, thereby possibly
preventing the transition from acute to persistent pain states. However, the contribution of
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other opioid receptor subtypes to LS remains to be determined. Thus, it is conceivable that
kappa opioid receptors (KOR) may also exert a compensatory long-lasting antinociceptive
response to repress hyperalgesia after injury.
MORCA suppresses inflammatory pain in part, via inhibition of AC1 - cAMP
signaling during LS. Thus, pharmacological blockade of MORCA induces pain
reinstatement possibly through disinhibition of NMDA-AC1 pathway allowing an increase
in cAMP and downstream signaling transduction (Corder et al., 2013; Taylor and Corder,
2014). Recent evidence indicates a role of the c-AMP downstream target protein kinase A
(PKA) and exchange protein associated with cAMP (Epac) in LS (Fu et al., 2019). Less
appreciated; however, is whether males and females differ in LS endogenous control and
spinal maladaptive plasticity mechanisms. Therefore, we propose that endogenous
postoperative analgesia would be differentially mediated by tonic KOR-mediated
inhibition of AC1 and/or downstream c-AMP signaling proteins PKA and Epac in male
and female mice.
1.2 Overall Hypothesis and Specific Aims
This dissertation tests the overall hypothesis that tissue injury leads to sustained
activation of kappa opioid receptors (KOR) in the dorsal horn of the spinal cord that
maintains latent sensitization (LS) within a state of remission, via inhibition of adenylyl
cyclase-1 (AC1)-dependent pathways in male and female mice. To test this hypothesis, I
designed and performed several experiments to examine the following specific aims:
1.

Delineate the contribution of the opioid receptor subtypes to the remission
phase of LS.
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2.

Determine whether there are sex differences in postoperative endogenous
opioid receptor analgesia.

3.

Examine whether KOR antagonist-induced reinstatement of hyperalgesia is
associated with spinal nociceptive neuronal sensitization.

4.

Determine whether KOR postoperative endogenous analgesia (suppression
of LS) is mediated by inhibition of AC1 and/or downstream PKA and Epac
mechanisms.

5.

Investigate potential sex differences in KOR-dependent LS.
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CHAPTER 2. General Background

2.1 Overview of Pain: concepts and classification
Pain is a complex multidimensional experience. Subjective in nature, and
intrinsically associated with emotional and cognitive factors, it is defined by the
International Association for the Study of Pain (IASP) as “an unpleasant sensory and
emotional experience associated with actual or potential tissue damage or described in
terms of such damage” (Merskey H & Bogduk N, 1994). Thus, the pain experience
encompasses both a sensory-discriminative and affective-motivational component. The
first component denotes the perceptual nature of pain; location, intensity, and quality of the
noxious stimuli can be distinguished via neural processing in the thalamus and
somatosensory cortices. While, the latter refers to its psychological aspects mediated by
the limbic system (Basbaum et al., 2009; Braz et al., 2014). Both pain dimensions can be
assessed experimentally. The sensory component is commonly measured in rodents and
human laboratory studies using stimulus-evoked tests such as von Frey filaments (Tena et
al., 2012; Wildgaard et al., 2012), and thermal assays (Woolfe, 1944; Hargreaves et al.,
1988). These assays employ physiological stimuli (i.e., mechanical, thermal, chemical) to
the limbs (or face) to assess changes in pain thresholds determined by the withdrawal or
escape latency from innocuous or noxious stimuli (Deuis et al., 2017). Similarly, the
affective-motivational dimension of pain is characterized by a negatively reinforcing
component that can be defined in preclinical studies using motivation to seek pain relief
assays in rodents such as Conditioned Place Preference or Conditioning Place Avoidance
paradigms (He et al., 2012; Griggs et al., 2015). While, it is assessed in the clinical setting
by self-report pain scales or self-administered questionnaires (Hardt et al., 2000; Martin et
5

al., 2019). This dissertation will focus primarily on stimulus-evoked tests (von Freyfilament) to assess mechanical hypersensitivity following surgery and pharmacological
manipulations of the opioid receptor systems.
As previously highlighted, pain is highly subjective and relies on patients’ selfreport. Thus, the term nociception, defined as neural processes of noxious stimuli detection
and processing (Basbaum et al., 2009) better applies to preclinical research, thereby it will
be used throughout this work. Acute (nociceptive) pain is fundamental for survival, as it
serves as a protective apparatus to inform the organism about imminent threats to avoid
further tissue damage and allow healing. Nociceptive stimuli are encoded by specialized
subpopulations of peripheral neurons, so-called nociceptors that transmit the noxious
signals to the first relay center of information in the CNS, the dorsal horn of the spinal cord
(or subnucleus caudalis in the brainstem for facial and cephalic stimuli). There the noxious
signals are processed and modulated before ascending to the higher centers in the brain
where the pain is perceived. The importance of acute pain is underlined in individuals with
congenital insensitivity to pain, in which the inability of detecting noxious stimuli due to
non-functional nociceptors leads to repeated severe injuries and reduced life expectancy
(Cox et al., 2006; Goldberg et al., 2007).
Pain is often categorized based on its duration. Acute pain is short-lived, lasting
from minutes to several weeks, and has a distinct etiology, such as tissue damage,
inflammatory processes or surgical intervention. If undertreated, acute pain may progress
to persistent pain states, lacking its biological function and becoming a disorder itself.
Chronic pain is multifaceted, accompanied by physical and psychiatric comorbidities, and
is, therefore, one of the most critical challenges in the clinic setting. It can exacerbate over
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time and persist from 4 months (IASP) to years, or even a lifetime. It may arise from
unremitted injuries (low back pain, postoperative pain), or be associated with a disease
(i.e., rheumatoid arthritis, diabetes). However, many of these clinical entities lack a clear
etiologic factor, such as fibromyalgia and chronic daily migraines. In an attempt to solve
this gap in the pain classification, the IASP recently adopted the terminology of nociplastic
pain to embrace the conditions that arise from altered nociception but are devoid of a
recognizable causal factor or associated disease (IASP, 2017). Moreover, chronic pain
patients can suffer from constant pain or experience episodes of remission as in low back
pain or persistent postoperative pain. In this dissertation, we adopted a preclinical model
of persistent postoperative pain due to its high prevalence and incidence, and identifiable
etiology that allows the investigation of putative mechanisms involved in the transition
from acute to chronic pain.
2.2 Postoperative pain: epidemiology and therapeutics
It is estimated that approximately 40% of chronic pain patients report that their
symptoms were initiated after trauma or surgical intervention (Schug SA & Pogatzki-Zahn
EM, 2011). Over 300 million surgeries are performed annually worldwide (Weiser et al.,
2016) and up to 80% of patients may experience postsurgical pain (Apfelbaum et al., 2003).
Among them, women report higher postoperative pain levels than men (Storesund et al.,
2016), and recent evidence indicates that females are at higher risk to develop persistent
pain after surgery (Schug AS & Pogatzki-Zhan EM, 2011). Persistent postoperative pain
is a significant burden to society as it impairs the quality of life of 5% to 85% of patients
that undergo a variety of surgical procedures every year (Schug AS & Pogatzki-Zhan EM,
2011).

It is defined as constant or intermittent pain in the surgical site (primary
7

hyperalgesia) or surrounding area (secondary hyperalgesia) that persists for at least three
months after the surgical procedure (Macrae, 2008; Werner and Kongsgaard, 2014). The
pain exhibits both inflammatory and neuropathic features as transoperative nerve damage
may occur (Kehlet et al., 2006; Haroutiunian et al., 2013).
The increased rate of chronic postoperative pain reflects, at least in part, the
inadequacy of currently available treatments. It is also possibly due to a disconnect between
the findings of fundamental research and clinical practice (Gerbershagen et al., 2014;
Cooper et al., 2016). To date, opioids remain the first line of treatment for acute
postoperative pain; however, its adverse effects including nausea, vomiting, and
constipation, the risk of respiratory depression, dependence, and addictive properties
compromise its effectiveness (Al-Hasani and Bruchas, 2011). Moreover, opioids are less
efficacious in cases with a strong neuropathic component, and when used preoperatively
increase the likelihood of persistent pain after surgery (VanDenKerkhof et al., 2012).
Current guidelines advise multimodal protocols encompassing cyclooxygenase inhibitors2 (COX-2) and NMDA antagonists. When neuropathy is present, drugs that reduce
neurotransmission and membrane stabilizers are recommended perioperatively (Chou,
2016). A recent meta-analysis supports the use of the α2δ ligands, gabapentin and
pregabalin, perioperatively to reduce the risk of persistent surgical pain (Clarke et al.,
2012). Despite the multitude of available therapies to treat acute postoperative pain, there
is no highly effective prophylactic drug to manage chronic postsurgical pain. Therefore,
drugs with potent analgesic properties and low addictive effects are warranted.
Here, we adopted a preclinical model of postoperative pain where a 5mm incision
is performed on the mouse hindpaw through the glabrous skin, fascia and plantaris muscle
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under general anesthesia, precipitating non-evoked guarding behavior of the limb that lasts
1 to 2 days and mechanical hypersensitivity that persists up to 3 weeks (Pogatzki and Raja,
2003). The intraoperative procedure of skin and fascia incision, muscle retraction and
behavioral presentation closely recapitulate the postoperative pain phenotype in patients
(Pogatzki-Zahn et al., 2007; Pogatzki-Zahn et al., 2017). After hyperalgesia subsides,
pharmacological approaches are used to target the opioid receptor system and key pain
modulators of spinal neuroplasticity, which in turn leads to reinstatement of pain behavior
and replicates persistent postsurgical states in patients. This model allows us to investigate
potential novel therapeutic targets involved in chronic pain consolidation such as AC1 and
downstream proteins Epac1/2.
2.3 Anatomy of nociceptive circuitry in the dorsal horn of the spinal cord
In the periphery, free nerve terminals from primary afferent neurons transduce
noxious stimuli into electrical signals (action potentials) that are conveyed to the CNS. The
dorsal horn of the spinal cord is the primary point of conversion of nociceptive inputs from
the periphery to high centers in the brain. The dorsal horn receives information from
heterogeneous groups of neurons responsible for processing and intense modulation of
noxious inputs before these signals ascend to the brain, where pain perception occurs. The
dorsal horn neurons are comprised of four groups: (1) central terminals of primary
afferents; (2) interneurons; (3) projection neurons; (4) descending axons from the
brainstem (Todd A and Koeber H, 2015). This work focuses on the first three populations
of neurons involved in the processing and modulation of nociceptive signals in the spinal
cord.
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The dorsal horn neurons are organized within a distinct laminar pattern (I-VI)
according to their functional class (Rexed, 1952). The superficial dorsal horn is the primary
region of relay for the primary afferent neurons and is comprised of laminae I or marginal
layer, and lamina II or substantia gelatinosa. Interneurons predominate in laminae I-III,
while the deeper laminae IV-VI are sites of synapse of primary sensory and projection
neurons (Figure 2.1.A) (Basbaum et al., 2009; Braz et al., 2014; Todd, 2017).
2.3.1 Primary sensory afferent inputs into the dorsal horn
Nociceptive primary afferents are specialized peripheral sensory neurons that
encode intense, noxious (i.e., mechanical, thermal, chemical) stimuli from the periphery
into the dorsal horn. Nociceptors are pseudo-unipolar neurons; the body of the neuron
arising from the limbs and trunk lies on the dorsal root ganglia (DRG). Their axons diverge
from the DRG to give rise to peripheral branches that innervate the skin, viscera,
musculoskeletal system, and blood vessels; and central terminals that synapse with secondorder neurons in the dorsal horn.
The primary afferent neurons are somatotopically organized in humans and
animals. In mice, the innervation of the hindpaw and lower limbs is supplied by three
subdivisions of the sciatic nerve: tibial, common peroneal and sural nerves that emerge
from the lumbar spinal nerves L3-L5. The sciatic nerve in mice is composed predominantly
of fibers originating at the L3 and L4 DRGs. Retrograde labeling and behavioral studies
demonstrated that in the C57Bl/6 mouse strain, the primary anatomical and somatosensory
contribution is predominantly provided by L4 (Rigaud et al., 2008). Therefore, in our
immunofluorescent assay, we evaluated the cellular markers at the L4 segment of the dorsal
horn of the spinal cord.
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Figure 2.1. Dorsal horn pain transmission pathways.
(A) Close sagittal view of the dorsal horn of the spinal cord. The distinct populations of
primary afferent fibers synapse with projection neurons in laminae I (red) and V (purple),
and interneurons from laminae II outer (green) to IV (black). (B) Ascending tracts from the
dorsal horn to the higher centers of the brain [Adapted from Braz et al., 2014].
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Based on their physical properties, the nociceptors are classified into two main
groups: A-delta (Aδ), and C-fibers. Aδ fibers are medium in diameter and thinly
myelinated, with conduction velocity >2m/s. They project to lamina I and V where they
synapse with projection neurons. They are highly discriminative and are thought to mediate
fast, sharp, aching, well-localized pain. Conversely, C-fibers are small in diameter,
unmyelinated, and therefore have slower conduction velocity (< 2m/s). The C-fibers are
subdivided into peptidergic and non-peptidergic subsets, expressing substance P (SP),
calcitonin gene-related peptide (CGRP), and transient vanilloid receptor, isoform 1
(TRPV1) receptors; and isolectin IB4 respectively. The peptidergic C-fibers project to
lamina I and lamina II outer; whereas non-peptidergic fibers project to lamina II inner and
synapse with interneurons, creating complex circuits within the dorsal horn. C-fibers
possibly mediate more diffuse and slow pain. Both, C- and Aδ fibers are polymodal,
responding to tactile, thermal and chemical stimuli.
The third subtype of peripheral sensory afferents is the large diameter and fast
conduction A-beta (Aβ) fibers. They project to lamina III-V and are responsive for low
threshold mechanical stimuli in physiological conditions (Figure 2.1.A). In the injury
setting, they become responsive to noxious stimuli, leading to increased hypersensitivity
to innocuous tactile stimulation, named allodynia (Basbaum et al., 2009; Todd, 2010; Braz
et al., 2014).
2.3.2 Dorsal horn interneurons
The nociceptive inputs delivered by the primary sensory neurons in the dorsal horn
are the subject of intense modulation by interneurons. Interneurons outweigh the other
neuronal cells throughout the dorsal horn. For example, the superficial lamina is composed
12

of a small fraction (> 5%) of projections neurons (Campbell et al., 1998), and at least 9095% of interneurons (Spike et al., 2003; Abraira and Ginty, 2013). While lamina II and III
are composed almost, if not exclusively, of interneurons. Functionally, interneurons can be
divided into excitatory and inhibitory cells (Todd, 2010). Excitatory interneurons
synthesize glutamate as their main neurotransmitter and can be detected by vesicular
glutamate transporter 2 (VGLUT2) immunoreactivity in their axons (Todd et al., 2003).
Inhibitory interneurons synthesize γ- aminobutyric acid (GABA) or glycine as their main
neurotransmitters and can be identified by vesicular GABA transporter (VGAT), and
glutamate decarboxylase (GAD67) (Mackie et al., 2003; Todd, 2010). Recently, the dorsal
horn

excitatory

and

inhibitory

interneurons

have

been

also

categorized

immunohistochemically by the expression pattern of the homeobox genes T-C-Leukemia
homeobox 3 (Tlx3) (Cheng et al., 2004; Xu et al., 2008b), and paired box gene2 (Pax2)
(Batista and Lewis, 2008) respectively.
Subpopulations of dorsal horn interneurons have also been identified based on their
electrophysiological properties and neurochemical markers. The identification of these
distinct populations of interneurons has been instrumental in uncovering the dorsal horn
circuits and their contribution to pathological pain (Miraucourt et al., 2007; Duan et al.,
2014; Petitjean et al., 2015; Peirs and Seal, 2016). Of particular interest for this dissertation
are the populations of opioid-expressing interneurons. MOR interneurons are expressed in
excitatory interneurons (Kemp et al., 1996) in lamina IIi and IIo (Corder et al., 2017; Wang
et al., 2018) and are thought to be part of a polysynaptic circuit involved in the inhibition
of ascending inputs via projection neurons in lamina I and V (Eckert et al., 2003; Chen et
al., 2005). Similarly, DOR-containing interneurons are mostly excitatory and located at
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the ventral aspect of lamina IIi. However, emerging evidence indicates that DOR and MOR
are co-expressed in a few subsets of interneurons, and they internalize and function
independently (Wang et al., 2018).
The expression of KOR in spinal circuits still debatable, IHC studies suggest that
they are expressed in inhibitory interneurons. Dynorphin, the KOR endogenous ligand, is
present in both excitatory and a subset of inhibitory interneurons of the superficial dorsal
horn (Todd, 2010; Boyle et al., 2017). In the setting of inflammatory pain, inhibitoryexpressing dynorphin interneurons play a central role in the mechanical gate circuitry
precluding the development of mechanical allodynia (Duan et al., 2014). However, spinal
dynorphin peptide exerts not only anti-nociceptive, but also pro-nociceptive actions
(Podvin et al., 2016). For example, in preclinical models of neuropathic pain and chronic
inflammation, upregulated spinal dynorphin promotes hyperalgesia possibly via an opioidindependent mechanism (Tan-No et al., 2004; Lai et al., 2006; Luo et al., 2008).
2.3.3 Ascending pathways from dorsal horn to the brain
Nociceptive signals from the dorsal horn are transmitted to the brain via projection
neurons located within lamina I and the deep dorsal horn. The projection neurons are
mostly concentrated in lamina I and are nociceptive specific. Conversely, the deep dorsal
horn contains nociceptive specific and wide-dynamic range neurons (WDR) that are
sensitive to both innocuous and noxious stimuli (Braz et al., 2014). Immunohistochemical
studies identified that the vast majority of lamina I and some deep dorsal horn projection
neurons are neurokinin 1 receptor (NK1) positive cells that are activated upon release of
SP from peptidergic nociceptors (Mantyh et al., 1995; Lawson et al., 1997; Todd et al.,
2002).
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From lamina I and V projection neurons, noxious inputs travel to the contralateral
side and ascend to higher brain centers via the spinothalamic and spinoreticulothalamic
tracts (Figure 2.1.B). The NK1 positive cells form synapses with neurons within the lateral
parabrachial nucleus (PBN), rostral ventral medulla (RVM), and periaqueductal gray
(PAG) and send projections to six distinct nuclei in the thalamus (Todd et al., 2002; Craig,
2003). From the thalamus, third order neurons convey to the primary (S1) and secondary
(S2) somatosensory cortices, where conscious perception is established, and the
discriminative aspects of pain are recognized. Alternatively, the PBN sends connections
to limbic structures promoting modulation of the affective and contextual facets of pain
(Ossipov et al., 2014).
2.4 Nociceptive plasticity in the dorsal horn
As previously highlighted, the dorsal horn is a primary integrative center for
transduction and processing of nociceptive information. Thus, the spinal nociceptive
circuits are under the constant influence of afferent inputs and modulation from descending
controls to adapt to potential damage. It is generally recognized that tissue injury leads to
peripheral sensitization and increased responsiveness of dorsal horn nociceptive neurons
to normal and sub-threshold afferent inputs, a process termed central sensitization (IASP),
that is implicated in the development of persistent pain states (Latremoliere and Woolf,
2009; Sandkuhler and Gruber-Schoffnegger, 2012).
Central sensitization relies on NMDA receptor (NMDAR) activity. For instance,
perioperative non-selective NMDA antagonist administration reduces postoperative pain
in rodents (Pogatzki et al., 2000; Shen et al., 2016) and patients (Stubhaug et al., 1997). At
the cellular level, NMDAR activation leads to increased cytosolic calcium (Ca 2+) and
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subsequent activation of several downstream substrates such as Ca2+/calmodulin-sensitive
adenylyl cyclases (Zhuo, 2012), and the kinases PKA, PKC and extracellular signalregulated kinase (ERK1/2). These kinases modulate the activity of glutamate ionotropic
receptors and trigger transcriptional events (Kawasaki et al., 2004; Latremoliere and
Woolf, 2009). The consequent increased excitability and efficacy of dorsal horn synapses
following injury results in a central amplification response and enlargement of receptive
fields which leads to pain from normally innocuous stimuli (allodynia) and heightened pain
sensitivity to noxious stimuli (hyperalgesia) at neighboring non-injury sites (secondary
hyperalgesia) that are commonly observed in chronic pain conditions (Woolf, 2007, 2011).
In this work, we used a series of manual von Frey filaments with incremental force
increases to evaluate punctate hyperalgesia or allodynia (Chaplan et al., 1994). As the
distinction between allodynia and hyperalgesia in rodent models of pain is challenging, the
term hypersensitivity is commonly applied throughout this dissertation. In addition, we
evaluated nociceptive plasticity in the dorsal horn using immunofluorescence of
phosphorylated ERK (pERK), as a marker of central sensitization.
2.5 Latent central sensitization as a model to investigate the transition from acute to
chronic pain states
The central sensitization of dorsal horn nociceptive neurons induced by tissue
trauma can persist beyond healing and recovery from behavioral signs of hyperalgesia.
This persistent spinal sensitization is outweighed by tonic activity of the inhibitory systems
in a silent form of neuroplasticity named latent sensitization (LS) (Figure 2.2) (Solway et
al., 2011; Taylor and Corder, 2014; Walwyn et al., 2016). Previous studies indicate that
sensitization of spinal neurons arising from surgical incision facilitates the recruitment of
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opioid receptors (Nagakura et al., 2008). Likewise, compelling data from our laboratory
indicate that LS is maintained in a remission phase by mu opioid receptor constitutive
activity (MORCA). For example, administration of MOR inverse agonists elicited
behavioral signs of withdrawal and hyperalgesia when given 21 days after hindpaw
injection of Complete Freund’s Adjuvant (CFA) or paw incision, but not in sham animals.
Moreover, this injury-induced spinal sensitization lasts at least several months under the
inhibitory control of mu opioid receptor systems (Corder et al., 2013).
Interestingly, LS can be transiently unmasked by Gi/o-protein receptor antagonists
(Campillo et al., 2011; Solway et al., 2011; Walwyn et al., 2016), chronic administration
of opioid agonists (Celerier et al., 2001; Li et al., 2001; Lian et al., 2010) and stress (Rivat
et al., 2007; Le Roy et al., 2011; Romero et al., 2017; Chen et al., 2018a). Therefore, LS
models resemble episodic chronic pain conditions triggered by, i.e., stressors or subsequent
injury and that are characterized by periods of remission. Thus, it may represent a critical
stage of pain vulnerability. In summary, these studies suggest that sustained signaling of
endogenous opioid receptor systems exert a crucial role in the modulation of pain after
injury, and any impairment in these protective systems may result in persistent pain states.
Therefore, LS is a robust, highly repeatable phenomenon, well characterized in rodents
(Taylor and Corder, 2014; Marvizon et al., 2015) and observed in a subset of human
subjects (Pereira et al., 2015b; Pereira et al., 2015a). As such, it is a suitable model to
investigate the poorly understood cellular and molecular mechanisms involved in the
transition from acute to pathological pain states.
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Figure 2.2 Schematic summarizing the sequence of events that occur after injury,
leading to a dynamic relationship between the systems that regulate analgesia and
pain.
Severe tissue injury triggers the development of latent nociceptive sensitization (LS, green
line). A compensatory kappa-opioid receptor-mediated (KOR, blue line) analgesia
silences LS, contributing to pain resolution (pain, red line). If the balance is disturbed, i.e.,
blockade of tonic KOR activity (dotted line), LS manifests as spinal neuronal sensitization
and pain reinstatement. [Adapted from Taylor & Corder, 2014].
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To help answer some of these questions, we employed a translational model of
chronic postoperative pain in mice, where a paw incision is performed, and numerous
behavioral signs of hyperalgesia are observed for 2-3 weeks (Pogatzki and Raja, 2003).
After the recovery of mechanical thresholds, the spinal nociceptive system is challenged
with either selective opioid antagonists and/or drugs targeting key pain modulatory
proteins, leading to the reinstatement of hyperalgesia (Figure 2.2). In chapter 3, we
investigate the spinal opioid receptor systems that counterbalance the sustained
pronociceptive inputs in the dorsal horn following surgical incision of the hindpaw. In
chapter 4, we designed experiments to uncover cellular signaling pathways underlying LS
after surgery and to investigate mechanisms by which spinal kappa opioid receptor activity
suppresses postoperative pain.
A major gap in the literature is that most animal studies on postoperative pain
focused on males. Although, women report high levels of postoperative pain (Storesund et
al., 2016), respond to opioid drugs differently than man (Gear et al., 1996a; Gear et al.,
1996b), and are at higher risk to develop persistent pain (Kehlet et al., 2006). Therefore,
we included female animal cohorts to assess putative sex differences in both arms:
endogenous opioid receptor analgesia and the persistent neuroplastic changes (LS)
associated with the induction and maintenance of chronic pain after surgery.
2.6. Mediators of spinal nociceptive transmission
2.6.1 Adenylyl cyclase, isoform 1 (AC1)
Adenylyl cyclase type I (AC1) is a membrane-bound calcium/calmodulin-sensitive
enzyme that catalyzes the synthesis of cyclic adenylyl monophosphate (cAMP) in
mammals. AC1 has been implicated in the modulation of synaptic plasticity and pain (Wu
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et al., 1995; Liauw et al., 2005; Wei et al., 2006; Zhuo, 2012; Corder et al., 2013), and it is
primarily expressed in the post-synaptic membrane of central and adrenal neurons and
retinal cells (Xia et al., 1993; Xia and Storm, 1997; Conti et al., 2007; Wang et al., 2011).
AC1 links NMDA activity-dependent increases of intracellular calcium and downstream
cAMP signaling pathways, functioning as a key protein for the induction of pain-related
plasticity in the CNS. Consequently, AC1 pharmacological or genetic manipulation does
not alter nociception but may impact the development of persistent pain states (Vadakkan
et al., 2006; Zhuo, 2012). For example, animals receiving systemic administration of the
selective AC1 inhibitor, NB001, and AC1KO mice show reduced mechanical hyperalgesia
after peripheral inflammation or nerve injury (Wei et al., 2002; Wang et al., 2011; Corder
et al., 2013; Griggs et al., 2017). Moreover, AC1 mutant mice exhibit reduced spinal LTP
induced by co-administration of serotonin and cAMP-induced by forskolin in the spinal
cord slices of adult mice (Wang and Zhuo, 2002), and reduced activation of ERK signaling
following peripheral inflammation (Wei et al., 2006). Similarly, AC1 is required for the
development of hyperalgesia in the late stages of a preclinical model of chronic
musculoskeletal pain (Vadakkan et al., 2006).
Conversely, AC1 is tonically inhibited by opioids and other Gi/o–coupled receptors.
Cumulative evidence from our laboratory indicates that AC1 is necessary for the
maintenance of LS (Corder et al., 2013). In summary, activation of AC1 leads to increased
intracellular cAMP levels that target downstream effector proteins engendering sustained
nociception. In Chapter 3, we investigate the hypothesis that KOR signaling opposes LS
following surgical incision via prolonged inhibition of AC1 and one or both cAMP target
proteins: protein kinase A (PKA) and exchange protein activated by cAMP (Epac). We

20

also explore potential sex differences in these c-AMP-mediated pronociceptive pathways
of LS.
2.6.2 Protein Kinase A (PKA)
Protein phosphorylation is a crucial mechanism for the regulation of nociceptive
signal transduction and transmission in the pain pathways. Protein kinase A (PKA) is a
classic cAMP-dependent kinase (Walsh et al., 1968) that has been implicated in the
regulation of nociception and pain-related synaptic plasticity in the spinal dorsal horn
(Sandkuhler, 2007; Latremoliere and Woolf, 2009). PKA is a heterotetrameric complex
composed of two regulatory and two catalytic subunits. It is activated upon binding of
cAMP to its regulatory domains that lead to dissociation of the catalytic subunits, which in
turn activate a myriad of intracellular substrates (Cheng et al., 2008).
Recent evidence from our laboratory indicates that PKA contributes to LS after
peripheral inflammation and nerve injury (Fu et al., 2019). PKA contributes to the
enhancement of spinal synaptic plasticity via phosphorylation of glutamate ionotropic
receptors following peripheral inflammation or robust noxious stimuli. For example,
phosphorylation of (alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid) AMPA
receptors GluR1 subunits leads to increased receptor trafficking and membrane insertion
(Fang et al., 2003; Latremoliere and Woolf, 2009). Similarly, PKA-related phosphorylation
of the NR1 subunit of NMDAR (Zhou et al., 2000) enhances receptor function and leads
to the development of hyperalgesia (Caudle et al., 2005; Gao et al., 2005). Taken together,
these findings indicate that activation of PKA after injury potentiates the expression and
function of the postsynaptic ionotropic glutamatergic receptors, neurotransmitter release
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and spinal synaptic transmission, and possibly contributing to enhancing persistent pain
states (Aley and Levine, 1999; Araldi et al., 2015, 2016).
2.6.3 Exchange protein directly activated by cAMP (Epac)
AC1 - cAMP signaling can also modulate nociceptive plasticity via PKAindependent pathways. Epacs (Epac, isoform 1 and Epac, isoform 2) are highly conserved
cAMP sensor proteins that act as guanine nucleotide exchange factors for small GTPases
(de Rooij et al., 1998; Bos, 2003, 2006). Epac 1 is ubiquitously expressed, while Epac 2
is primarily neuronal (Kawasaki et al., 1998). Epacs are activated as cAMP binds to the
regulatory motif (CNB) leading to its dissociation from the catalytic region and subsequent
activation of Rap GTPases (Chen et al., 2013). In vitro and in vivo studies indicate that
Epacs mediate mechanical hyperalgesia (Wang et al., 2013; Singhmar et al., 2016);
following nerve injury (Singhmar et al., 2018) and persistent inflammation through
activation of protein kinase C (PKC) in small, non-peptidergic fibers (Griffin, 2005; Hucho
et al., 2005). Furthermore, peripheral inflammation enhances the expression of Epacs and
subsequent up-regulation of multiple PKC isoforms in the DRG (Gu et al., 2016).
Similarly, recent evidence suggests that Epac 1 and Epac 2 are activated during LS induced
by surgical incision (Matsuda et al., 2017). Altogether, these results indicate that Epacs are
key modulators in the development of persistent pain states, and therefore may represent a
promising therapeutic target for pain management.
2.6.4 Phosphorylated Extracellular Signal-Regulated Kinase (pERK)
Extracellular signal-regulated kinase (ERK) is a member of the mitogen-activated
protein kinase (MAPKs) family which is important for intracellular signaling transduction.
The ERK isoforms 1 (ERK1) and 2 (ERK2) are expressed in the spinal cord and are
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activated in the dorsal horn following tissue injury or inflammation. ERK phosphorylation
is found most abundantly in lamina I and II, where most nociceptor afferents relay and
NK1 neuronal body are located, and are scattered in lamina III to V of the spinal cord (Ji
et al., 1999; Zhuang et al., 2005; Ji et al., 2009).
Tissue injury promotes the activation of multiple neurotransmitter systems and
kinases that leads to ERK phosphorylation and contributes to neural plasticity and
nociceptive sensitization. For example, peripheral inflammation leads to the release of SP
and glutamate, which in turn actives neurokinin 1 receptor (NK1R) or AMPAR and
NMDAR. The subsequent rise of intracellular Ca+2 elicits the activation of AC1 and several
cAMP effectors including PKA and PKC. All these substrates are reported to contribute to
ERK1/2 activation in vivo and in ex vivo spinal cord slices (Ji et al., 1999; Kawasaki et al.,
2004; Wei et al., 2006; Chen et al., 2018c). Once activated, pERK perpetuates the
phosphorylation and trafficking of glutamatergic receptors (Kohno et al., 2008; Ji et al.,
2009), and contributes to CREB phosphorylation and transcription of genes such as c-Fos
and prodynorphin (Kawasaki et al., 2004). Thus, pERK contributes to both induction and
maintenance of central sensitization, and possibly the pronociceptive component of latent
sensitization (Chen et al., 2018c).
In naïve animals or baseline conditions, intense noxious stimuli are necessary to
activate ERK, while low threshold or mechanical stimuli (i.e., light touch) are sufficient
for ERK activation after injury (Wang et al., 2004; Gao and Ji, 2010). Moreover, pERK
expression is increased after Therefore, in chapter 3 and 4 we will evaluate pERK
immunoreactivity in the dorsal horn, as a marker of central sensitization, which is
detectable 5-10 minutes after nociceptive insult (i.e., pharmacological blockade of opioid
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receptors) (Gao and Ji, 2009) followed by innocuous (i.e., light touch) stimuli (Ji et al.,
2009; Corder et al., 2013) in post-incisional and sham animals.
2.7 Endogenous opioid receptor systems and pain
The opioid receptor system consists of four highly conserved seven-transmembrane
G-protein coupled receptors (GPCRs), the classic mu (MOR), delta (DOR), kappa (KOR),
and the closely-related family nociceptin opioid peptide (NOP) receptors. These receptors
are ubiquitously expressed in the peripheral tissues and central neurons (Al-Hasani and
Bruchas, 2011) (Figure 2.3), neuroendocrine and immune cells. All four receptor subtypes
were characterized molecularly and pharmacologically (Table 2.1). Upon binding of
endogenous ligands (beta-endorphin, enkephalin, dynorphin, and nociception/orphanin
FQ) and/or exogenous agonists they exert potent antinociceptive effects (Yaksh, 1987;
Mansour et al., 1988; Yaksh et al., 1988). The ligands bind to open pockets composed by
the extracellular and transmembrane domains. All four receptor subtypes structures were
initially characterized in an inactive form upon binding of selective antagonists.
Remarkably, MOR and KOR were recently identified under their active state (Manglik et
al., 2016; Che et al., 2018). This configuration facilitates the development of new
compounds and has been the subject of excitement in the field of opioid pharmacology
(Manglik et al., 2012; Manglik et al., 2016).
Opioid receptor activation at different nervous system loci modulates spinal
nociceptive transmission via stimulation of G protein-dependent and independent signaling
pathways. All four receptor subtypes are coupled to a heterotrimeric inhibitory Gαi/o─Gβγ
protein complex. Ligand binding or increased constitutive activity (Corder et al., 2013;
Polter et al., 2017) alters the opioid receptor configuration, where Gαi/o and Gαβγ subunits
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dissociate, leading to the inhibition of adenylyl cyclase - cyclic adenosine monophosphate
(cAMP) - dependent signaling pathways (Childers, 1991; Childers et al., 1992; Reisine and
Bell, 1993). As a result, the opening of voltage-gated Ca2+ channels (VGCC) is reduced
(Dickenson et al., 1987; Sullivan et al., 1989; Kohno et al., 1999; Kondo et al., 2005),
decreasing neuronal excitability and neurotransmitter release. Additionally, at the postsynaptic membrane Gαβγ complex increases G protein-coupled inwardly rectifying
potassium channel (GIRK) conductance, which further hyperpolarizes the neuron
(Logothetis et al., 1987). Collectively, opioid receptor agonists decrease neuronal
transmission and promote robust antinociception (For comprehensive review please see
(Al-Hasani and Bruchas, 2011; Corder et al., 2018).
This dissertation will focus primarily on the pharmacological effects of antagonists
of the classic opioid subtypes (MOR, DOR, and KOR, Table 2.2) in unmasking
postoperative LS and putative sex differences in opioid receptor analgesia (Chapter 3).
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Figure 2.3. Loci of analgesic actions of opioids in pain pathways.
Opioid receptors are expressed throughout the nociceptive pathways. Endogenous and
exogenous opioids exert their analgesic actions in the peripheral tissues (1), pre- and postsynaptically in the spinal cord (2), and brain (3) (black arrows, pain transmission =
ascending pathways); and in descending modulatory tracts from the brainstem - midbrain
periaqueductal grey (PAG) and rostral ventromedial medulla (RVM) (red arrows, pain
modulation = descending pathways). (Adapted from Al Hasani & Bruchas, 2011).
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Table 2.1 Opioid receptor systems gene and pharmacological characterization.
The classic opioid subtypes’ and respective genes with endogenous and exogenous ligands.
[Adapted from (Puig and Montes, 1998; Dickenson and Kieffer, 2013)].
Opioid
Receptor
Subtype
Gene

MOR

DOR

KOR

OPRM1

OPRD1

OPRK1

Endogenous
Peptide
Precursor
Endogenous
Agonists

Pro-opiomelanocortin
(p-POMC)

Pro-enkephalin
(p-PENK)

Pro-dynorphin
(p-Dyn)

β-endorphins
Enkephalins

Enkephalins

Dynorphins

Agonists

Codeine

Codeine

Codeine

Selective
Agonists

DAMGO
Morphine

Deltorphin
DPDPE

Enandoline
Salvinorin A (N)
U50,488H
U69,593

Antagonists/
Inverse
Agonists
Selective
Antagonists

Naloxone
*Naltrexone

Naloxone
*Naltrexone

Naloxone
*Naltrexone

*CTOP

*Naltrindole
*TIPPψ

CYM51317
GNTI (L)
JDTIC (L)
*LY2456302/
*(CERC 501)
*Nor-BNI (L)
Zyklophin

* Drugs used in this dissertation.
L= long-acting; N= natural product.
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2.7.1 Delta opioid receptors
Delta opioid receptors (DOR) were the first opioid receptor subtype cloned (Evans
et al., 1992; Kieffer et al., 1992). Similarly to MORs and KORs, they are highly conserved
across species (Knapp et al., 1995). DORs regulates both nociception and opioid tolerance.
Their analgesic effects at the spinal cord level were confirmed in studies using DOR KO
mice (Zhu et al., 1999) and pharmacological manipulations. A distinct feature of DOR is
that it is found mostly in intracellular structures (Cahill et al., 2001) of sensory neurons and
traffic to the cell surface in response to agonist administration (Gendron et al., 2006),
chronic inflammation or opioid administration (Cahill et al., 2003). In contrast, recent
studies using DOR-GFP mice revealed a relatively high expression of DORs at the
neuronal membrane under physiological conditions (Scherrer et al., 2009; Wang et al.,
2018).
Several lines of evidence suggest that DORs exert their analgesic actions, at least
in part, due to heterodimerization with MORs (Gomes et al., 2000; Kieffer and GaveriauxRuff, 2002; Gendron et al., 2006). Although, recent studies using DOR-GFP indicate that
despite significant (~50%) co-localization with MORs in projection neurons in lamina I,
they are expressed mostly in distinct populations of interneurons and function
independently (Wang et al., 2018). In addition, DORs are present in the non-peptidergic
and mechanosensory myelinated nociceptors that project to the skin and are involved in
mechanical hypersensitivity in chronic pain states (Scherrer et al., 2009; Bardoni et al.,
2014). Thus, DOR activation is involved in the control of mechanical pain. Moreover,
microinjection of DOR agonists in the rostral ventral medulla (RVM) leads to
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antinociceptive effects in chronic inflammatory models of pain, indicating a supraspinal
descending inhibitory control of DORs (Hurley and Hammond, 2000).
2.7.2 Mu opioid receptors
MOR is the main target of most opiate drugs available to treat severe pain. It
promotes robust antinociceptive effects once activated by its endogenous peptides βendorphin or exogenous ligands such as morphine. However, prolonged use of opioid
agonists are associated with multiple severe adverse effects including tolerance,
dependence, respiratory depression and opioid induced hyperalgesia (Al-Hasani and
Bruchas, 2011).
MORs are broadly expressed throughout the pain pathways. Their expression is
enhanced in unmyelinated peptidergic fibers or thermonociceptors (Vetter et al., 2006;
Chen and Pan, 2008; Bardoni et al., 2014) possibly involved in the control of postoperative
pain. The presence of MOR in these afferent fibers also contributes to the development of
opioid tolerance and hyperalgesia (Araldi et al., 2015; Corder et al., 2017; Araldi et al.,
2018). In the spinal dorsal horn, MOR is present in lamina I projection neurons and
subpopulations of lamina II interneurons (Corder et al., 2017; Corder et al., 2018; Wang et
al., 2018). In the setting of injury, spinal MORs are thought to promote long-lasting
endogenous analgesia via increased constitutive activity (Corder et al., 2013)
predominantly in central terminals of primary afferents (Severino et al., 2018).
Spinal nociceptive transmission is highly modulated by MOR actions in supraspinal
sites as well. Microinjections of MOR agonists or electrostimulation of the periaqueductal
gray (PAG) and rostral ventromedial medulla (RVM), key modulatory areas in the
brainstem, promotes robust antinociception. These effects are attributed to MOR inhibition
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of excitatory (“on cells”) or disinhibition of inhibitory (“off cells”) in the RVM that send
projections directly to the dorsal horn (Basbaum and Fields, 1984; Ossipov et al., 2014).
Recent studies identified two distinct populations of “off cells” as GABAergic neurons coexpressing Penk (proenkephalin) to inhibit nociceptive transmission in the dorsal horn, and
a population of MOR-expressing cells that synapses with Penk-positive interneurons in the
dorsal horn that modulates mechanonociception presynaptically (Francois et al., 2017;
Corder et al., 2018). Therefore, MOR is a potent endogenous analgesic system promoting
antinociceptive effects in different sites of the nervous system.
2.7.3 Kappa opioid receptors
KOR is highly expressed in all levels of the pain neuroaxis and descending
modulatory circuits. Under physiological conditions, KOR is activated upon binding of its
endogenous peptide ligand, dynorphin (Goldstein et al., 1979; Goldstein et al., 1981;
Fischli et al., 1982), which is expressed and released from nerve terminals in the CNS to
selectively act on peripheral or central KORs (Chavkin et al., 1982; Wagner et al., 1991;
Chavkin, 2013). Depending on the site of action, the activation of the KOR-dynorphin
system is implicated in numerous physiological processes and pathologies including
analgesia (Millan et al., 1985; Spampinato and Candeletti, 1985; Clemente et al., 2004;
Auh and Ro, 2012; Snyder et al., 2018), paradoxical hyperalgesia (Tan-No et al., 2002; Lai
et al., 2006; Luo et al., 2008), stress (Knoll and Carlezon, 2010; Chavkin, 2013; Xie et al.,
2017), mood disorders (Land et al., 2008; Carroll and Carlezon, 2013; Li et al., 2016), and
reinstatement of drug seeking (Sun et al., 2010; Jackson et al., 2015; Reed et al., 2018).
When activated by dynorphin or exogenous full or partial agonists, KOR promotes
analgesic effects via Gi/o signaling (Chavkin, 2011), while its aversive and psychomimetic
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effects are mediated by activation of mitogen-activated protein kinase MAPK (Bruchas et
al., 2007a; Land et al., 2008) in the brain. Emerging evidence indicates a possible
dynorphin-independent KOR activation after stress (Polter et al., 2017) and injury
(Walwyn et al., 2016).
2.7.3.1 Peripheral
In the periphery, KOR is present in free nerve terminals in the enteric mucosa and
skin to regulate neuroendocrine, immune functions (Hedner and Cassuto, 1987), and pain
(Joris et al., 1987; Stein et al., 1988; Moon et al., 2016; Snyder et al., 2018). In the setting
of inflammation, endogenous opioids are released from immune cells in a P38 MAPK
dependent process (Stein, 1991). Endogenous and exogenous opioids may penetrate the
perineurial barrier of nociceptors after inflammation to interact with opioid receptors and
promote analgesia (Stein, 1991; Antonijevic et al., 1995; Rittner et al., 2009). Alternatively,
there is speculation that KOR agonists may interact with receptors expressed on immune
cells (Snyder et al., 2018). The peripheral antinociceptive effects of KOR exogenous
agonists are well characterized. KOR activation attenuates neurogenic inflammation via
reduction of plasma extravasation and hyperemia induced by inflammatory mediators
(Snyder et al., 2018). Additionally, it decreases thermal (Joris et al., 1987), and mechanical
sensitivity after chronic inflammation (Auh and Ro, 2012). A recent study characterized
the expression of KOR in peptidergic nociceptors in the skin and visceral tissues and
implicated peripheral KOR in the modulation of mechanical pain associated with surgical
incision (Snyder et al., 2018).
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2.7.3.2 Spinal Cord
KOR is highly abundant in the superficial dorsal horn (lam. I and II) of the spinal
cord (Harris and Drake, 2001; Harris et al., 2004). It is present in the central terminals of a
subset of primary peptidergic afferent neurons in mice and humans, low threshold
mechanoreceptors and the dorsal column (Snyder et al., 2018). The expression of KOR in
projection and interneurons is not yet well characterized. KOR agonists delivered spinally
elicit analgesia in several pain models (Milan, 1990) and suppress chloroquine induceditch (Kardon et al., 2014). Similarly, the release of dynorphin from interneurons located in
the superficial dorsal horn reduce mechanical pain (Todd, 2017). Moreover, dynorphin
peptide i.t. administration leads to analgesia in acute pain models, an effect that is mediated
by KOR binding (Spampinato and Candeletti, 1985; Podvin et al., 2016).
Conversely, in chronic inflammatory and nerve injury models dynorphin
administration elicits hyperalgesia/allodynia via non-opioid pathways, possibly through
direct or indirect interaction with NMDA or bradykinin receptors (Vanderah TW et al,
1996; Tan-No K, et al., 2002; Lai et al., 2006, Luo MC et al., 2008). The effects of KOR
agonists in spinal nociceptive plasticity (LTP) yielded mixed results; some studies failed
to demonstrate an effect of KOR agonists in spinal field potentials (Buesa et al., 2008),
while others found KOR inhibitory effects on C-evoked potentials (Sullivan and
Dickenson, 1991) and voltage-gated Ca+2 currents (Snyder et al., 2018). Moreover,
systemic Norbinaltorphimine (Nor-BNI) administration three weeks after surgical incision
under remifentanil restored mechanical hyperalgesia in mice. In line with these results,
spinal administration of long-lasting KOR antagonists also elicited hyperalgesia three
weeks after intraplantar CFA injection in rodents, when the mechanical thresholds returned
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to baseline levels. It is important to note that the long-lasting KOR antagonists used in the
abovementioned studies have a delayed onset (Munro et al., 2012), off-target effects in
MOR (Horan et al., 1992) in high dosages, and are thought to act indirectly on KOR
through JNK-1 signaling, which in turn leads to KOR desensitization (Bruchas et al.,
2007b). Therefore, the precise effects of spinal KOR activation in chronic pain are still
unresolved.
Thus, throughout this work, we will investigate the effects of spinal KOR in chronic
postoperative pain using primarily the selective reversible short-acting antagonist
LY2456302 (currently known as CERC 501), which acts directly on KOR (Rorick-Kehn
et al., 2014b). Moreover, the vast majority of animal research focuses on the KOR effects
mediated by Gβγ or β-arrestin-independent signaling. Therefore, we further expand the
literature evaluating antinociceptive effects of kappa in chronic pain via components of G α
(AC1 and cAMP) signaling.
2.7.3.3 Brain
KORs are expressed in multiple brain loci. The dynorphin-KOR system is
implicated in the regulation of several brain psychopathologies. For example, KOR
regulation of the mesocorticolimbic circuitry underlies the etiology of mood disorders,
dysphoria and reinstatement of drug seeking (Cahill et al., 2014) through inhibition of
monoaminergic centers at several sites (Lalanne et al., 2014). The amygdala is an important
site for regulation of stress, and affective components of pain (Narita et al., 2006; Cahill et
al., 2014; Xie et al., 2017), while the RVM is a key site of modulation in inflammatory
pain. Microinjection of KOR agonist in the left central amygdala in rats “primed” with
sumatriptan infusion reveals reduction of paw mechanical thresholds, which is reversed by
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KOR blockers, implying pronociceptive actions of KOR (Xie et al., 2017; Navratilova et
al., 2018). Conversely, microinjection of KOR agonists in the RVM reduces mechanical
and thermal sensitization, effects that became more evident as inflammatory pain persists
(Hurley and Hammond, 2000; Schepers et al., 2008b; Schepers et al., 2008a). Therefore,
the modulatory effects of KOR systems in pain processing is dependent on the site of action
and regulatory functions.
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CHAPTER 3. Sex Differences in Kappa Opioid Receptor Inhibition
of Latent Postoperative Pain
This chapter is a similar version of the manuscript submitted to Neuropharmacology.
Donahue R.R., Lambert J., Smith B., and Taylor B.K. are additional authors of the
manuscript.
3.1 Abstract
Tissue injury induces an allostatic state of latent pain sensitization (LS) in the dorsal
horn neuron that is opposed in part by mµ-opioid receptor constitutive activity. Blockade
of this endogenous inhibitory activity with naltrexone or naloxone reveals LS as a
reinstatement of mechanical hypersensitivity. However, naltrexone or naloxone also bind
with significant affinity to delta and kappa opioid receptors. Therefore, to evaluate the
specific contribution of mu, delta, and kappa opioid receptors to endogenous inhibition of
LS, we performed plantar incision at the hindpaw, waited 21 days for the resolution of
hyperalgesia, and then intrathecally injected subtype-selective antagonists. We found that
neither of the two delta receptor-selective antagonists naltrindole (1µg) nor TIPP[Ψ] (110µg) changed mechanical thresholds. By contrast, the mu receptor-selective antagonist
CTOP (1-1000ng) dose-dependently reinstated mechanical allodynia, to a similar degree
in male and female mice. Similarly, the kappa receptor-selective antagonists Nor-BNI (0.110µg) and LY2456302 (0.1-10µg) reinstated mechanical allodynia. Furthermore,
LY2456302 (10µg) increased the expression of phosphorylated signal-regulated kinase
(pERK), a marker of central sensitization, in dorsal horn neurons but not glia. Sex studies
revealed that a lower (0.3µg) but not higher dose (10µg) of LY2456302 reinstated
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hypersensitivity to a greater degree in female as compared to male mice. Our results
suggest that spinal MOR and KOR, but not DOR, maintain LS within a state of remission
to reduce the intensity and duration of postoperative pain and that endogenous KOR but
not MOR analgesia is greater in female mice.
3.2 Introduction
Tissue injury induces a sustained form of neuronal plasticity, termed latent
sensitization (LS), that is kept within a state of remission by compensatory pain inhibitory
systems that include opioid, neuropeptide Y and alpha2-adrenergic receptor signaling
(Rivat et al., 2002; Campillo et al., 2011; Solway et al., 2011; Corder et al., 2013; Taylor
and Corder, 2014; Walwyn et al., 2016). Long-lasting mechanisms of endogenous opioid
receptor analgesia include mµ-opioid receptor constitutive activity (MOR CA) (Corder et
al., 2013; Walwyn et al., 2016); evidence for endogenous opioid inhibition of LS exists not
only in mice and rats, but also in human experimental pain models (Pereira et al., 2015b;
Pereira et al., 2015a). Some studies also indicate a contribution of delta-opioid receptor
(DOR) and kappa-opioid receptors (KOR) (Campillo et al., 2011; Walwyn et al., 2016; Xie
et al., 2017). However, these studies were limited to behavioral indices of pain and/or
animals received prior administration of a different drug. To address these deficiencies, we
performed plantar incision at the hindpaw, waited 21 days for the resolution of
hyperalgesia, and then intrathecally injected multiple doses of multiple subtype-selective
opioid receptor ligands. In addition to behavior, we also assessed touch-evoked changes in
the expression of phosphorylated extracellular signal-regulated kinase (pERK), a marker
of central sensitization of nociceptive neurons in the dorsal horn (Gao and Ji, 2009).
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Numerous studies report sex differences in the ability of exogenous KOR ligands
to modulate pain in both rodents (Mogil et al., 2003; Terner et al., 2003a; Terner et al.,
2003b; Sternberg et al., 2004; Lomas et al., 2007; Auh and Ro, 2012; Robinson et al., 2016)
and humans (Gear et al., 1996a; Gear et al., 1996b; Pande et al., 1996b; Pande et al., 1996a;
Gear et al., 1999). However, questions of sex differences in endogenous opioid receptor
analgesia have not been rigorously studied. To address this gap, we investigated whether
sex is a main factor in endogenous spinal MOR- and KOR-mediated inhibition of LS by
testing both male and female mice.
3.3 Materials and Methods
3.3.1 Subjects
Experiments were carried out in 8-12 weeks old male and female C57Bl/6 mice
(Charles Rivers Laboratories, Inc, Wilmington, MA). Mice were housed maximum 5 samesex littermates per cage in a temperature and humidity-controlled room (14:10hr light-dark
cycle, lights on at 6:00 am) with ad libitum access to food and water. The Institutional
Animal Care and Use Committee at the University of Kentucky, protocol (#2017-2768),
approved all procedures following American Veterinary Medical Association guidelines.
Mice were acclimated to the colony housing room for several days and then handled for 2
days by the experimenter before the initiation of the studies.
3.3.2 Plantar Incision Model of Postoperative Pain
Post-operative pain was induced by longitudinal incision of the plantaris muscle, as
previously described (Pogatzki and Raja, 2003; Jang et al., 2011). Under isoflurane
anesthesia (5% induction and 1.5-2% maintenance, via a nose cone) and antisepsis of the
left hind paw with Chlorascrub® then alcohol, a #11 scalpel blade was used to perform a
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5mm through the skin and fascia using, beginning 2mm from the proximal edge of the heel
extending towards the digits. The underlying muscle was raised with curved forceps,
extended 4 mm and incised longitudinally, leaving the origin and insertion of the muscle
intact. The overlying skin was closed with synthetic 5-0 sutures (PDS*II, Ethicon),
followed by application of antibiotic ointment was applied. Surgery was typically
completed within 5-10min. Sutures were removed on the post-operative day 10. Sham
controls received anesthesia but no surgical incision.
3.3.3 Direct Intrathecal (i.t.) Drug Delivery
As previously described (Fairbanks, 2003), non-anaesthetized mice were lightly
restrained in a towel, and a 30G x1/2 needle (Becton Dickinson) attached to a 25-µl
Hamilton micro syringe, was inserted into the subarachnoid space between the L5/L6
vertebrae. The needle was angled about 30-45 degrees with the horizontal plane and
slightly advanced until reflexive tail flick was confirmed, then 5 µl of drug or vehicle was
slowly administered. The needle was held in place for 30sec, to ensure the solution fully
enters the spinal canal, withdrawn, and then the mouse was returned to its testing chamber.
3.3.4 Drug Dosing
All Drugs or vehicle were intrathecally injected in a 5 µl bolus. The MOR selective
ligand D-Phe-c[Cys-Tyr-Trp-Orn-Thr-Pen]-Thr-NH2 (CTOP, Cat.#1578 Tocris) was
dissolved in sterile saline (0.9%NaCl) and injected at doses of 1 – 1000ng (Gendron et al.,
2007; Corder et al., 2013). Based on these doses we established dose response curves. The
DOR-selective ligand Naltrindole HCL (Sigma-Aldrich N115) was dissolved in sterile
saline and injected at doses of 0.1-10µg (Scherrer et al., 2009), H-Tyr-TicΨ [CH2-NH]
Phe-Phe-OH (TIPP[Ψ], gift from NIDA Drug Supply Program) was sonicated in ddH20 at
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30°C for 30 minutes and injected at doses of 1-10µg (Riba et al., 2002b; Riba et al., 2002a).
Doses of naltrindole equal to or greater than 10 μg and TIPP[Ψ] at 20 μg elicited adverse
effects such as itching, licking and tail biting, so we limited their use to a high dose of 1
μg of naltrindole and 10 μg of TIPP[Ψ]. The KOR-selective ligand norbinaltorphimine
dihydrochloride (Nor-BNI, 0347 Tocris) was dissolved in saline and injected at doses of
0.1-10µg. For Figures 3.4 and 3.6, LY2456302 (Rorick-Kehn et al., 2014a; Rorick-Kehn
et al., 2014b) was obtained from the NIDA Drug Supply Program, sonicated in ddH 20 at
30°C for 30 minutes, and 0.1-10µg was injected. For Figures 3.6, 3.7 and 3.8, LY2456302
was obtained from Med Chem Express, dissolved 1:1:8 in EtOH: Alkamuls EL-620,
Rhodia, Cranbury, NJ: saline, and injected at dose of 10 µg.
Testing began at day 21 after surgery to allow for mechanical thresholds to return
to pre-incision baseline levels. At this time, animals were assigned to experimental groups
by a laboratory colleague (RRD, WF) who kept the code until the experiments were
completed. On day 21, some animals received appropriate drug, or vehicle. After a sevenday washout, animals given drug on day 21 were given vehicle or higher dose of that same
drug on day 28. Conversely, animals given vehicle on day 21 were given drug on day 28.
This cross-over design was not used with the KOR ligands due to their extended half-lives.
3.3.5 Pain-Like Behavioral Assessment: Stimulus-Evoked
All animals were acclimated in a temperature and light controlled room within
individual Plexiglas boxes placed on the top of a stainless-steel mesh platform for 30 to 60
min prior to behavioral testing. Mechanical thresholds were assessed using an incremental
set of 8 von Frey monofilaments (Stoelting, Illinois), ranging in gram force from 0.008g to
6g. The filaments were applied perpendicularly to the ventral surface of the hindpaw lateral
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to the suture site with enough force to engender slight bending of the filament. A positive
response was characterized as a rapid withdrawal of the paw away from the stimulus fiber
within 5s. Left and right hindpaws were tested alternately. Using the up-down method
(Chaplan et al., 1994),

response patterns were logarithmically converted into 50%

withdrawal thresholds (in gram force). As previously described, animals were randomly
assigned to experimental groups in all studies. Investigators (LCP and RRD), blinded to
experimental groups by a research associate, and conducted all behavioral experiments.
3.3.6 Touched-evoked Phosphorylated Extracellular Signal-Regulated Kinase
(pERK)
As previously described (Corder et al., 2013), 21 days after surgery mice received
either vehicle or LY2456302 (10µg). Two hours after injection, mice were lightly
anesthetized with isoflurane (1.5%), and the ventral surface of the ipsilateral hindpaw was
mechanically stimulated with gentle 2-second stroke with a cotton swab from heel to toe.
This was repeated every 5s for 5min. After an additional 5 min pause, mice were deeply
anesthetized with isoflurane and transcardially perfused with cold 0.01M phosphate buffer
saline (PBS, Fischer Scientific) /heparin buffer (10,000 USP units/L), followed by 10%
phosphate formalin buffer. Lumbar spinal cords were harvested and post-fixed in the same
fixative overnight at 4oC, and then cryoprotected with 30%sucrose until total submersion
(1-3 days).
3.3.7 Histology and Immunohistochemistry
Transverse sections (30μm) from L3-L5 were obtained on a sliding microtome
(Leica, SM 2000R). A series of sections, each 240µ apart, was washed in 0.01M PBS,
blocked in 3% normal serum (goat or donkey; Gemini Bioproducts), containing 0.3%
40

Triton X-100 (Sigma Aldrich) in 0.01M PBS for 1h, and then incubated with primary
rabbit antibody anti-phosphorylated-ERK ½ antiserum (1:800, Cell Signaling) at 4 oC for
36 hours on a shaker (Fig.3.4, 3.6 and 3.7), or goat anti- -Iba1 (isoforms 1 and 3) (1:500,
Sigma Aldrich), and/or chicken anti-GFAP (1:1000, Abcam) at 4 oC overnight. The
following day, sections were again washed in 0.01M PBS and incubated for 1h at room
temperature with secondary conjugated antibodies (1:1000, Invitrogen: donkey anti-rabbit
Alexa Fluor 568, donkey anti-goat Alexa Fluor 488, goat anti-rabbit Alexa Fluor 568,
and/or goat anti-chicken Alexa Fluor 488. For neuronal co-staining, FITC-conjugated
mouse NeuN (MAB377X 1:500, EMD Millipore) was incubated for 1h at room
temperature (Fig.3.8). The sections were washed in 0.01M phosphate buffer, mounted and
cover slipped with mounting medium with DAPI (Vectashield, Vector laboratory). At least
five good quality sections from segment L4 were selected from each subject for
microscopy.
3.3.8 Microscopy
Fluorescence Microscopy. For quantification of pERK immunoreactivity, low
magnification images taken with Nikon TE-2000 microscope equipped with a 10X
objective were captured and analyses with NIS-Elements Software AR 4.13.05. An
examiner blinded to treatment and sex counted the number of positive pERK cells in
laminae I-II and III-V.
Confocal Microscopy. For double-label immunohistochemistry, confocal images
were acquired with a Nikon A1 Confocal Microscope System equipped with a 60X oilimmersion objective (numerical aperture 1.49) located in the Microscopy Core at the
Department of Biochemistry at the University of Kentucky Biomedical Biological Sciences
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Research Building. Laser excitation and emission windows for the different fluorophores
were as follows: Alexa Fluor 568 (Cy3) – excitation 543.5 nm, emission 543-633 nm,
Alexa Fluor 488 (EGFP) – excitation 488nm, emission 483-543nm, and DAPI - excitation
405nm, emission 423-483nm. Z-stacks images were obtained with 0.5mm slice thickness.
Images were processed using Nikon NIS-elements confocal software AR 4.30.02.
3.3.9 Statistical Analysis
Mechanical thresholds are summarized as mean values quoted with the
corresponding standard error (mean ± SEM). The effects of Drug and Time were analyzed
by two-way analysis of variance (ANOVA), followed by Bonferroni multiple correction
tests. Data were then re-plotted as area under the curve using the trapezoidal method and
integrative thresholds were analyzed using one-way or two-way ANOVA as appropriate,
followed by Bonferroni tests using Prism 8 (GraphPad, La Jolla, CA). Non-linear
regression analyses of Maximum Possible Effect (%MPE) were used to determine the
ED50 for each drug. %MPE was calculated as follows: % MPE = 100* (post-injection
threshold – preinjection threshold) / (post-injury threshold – pre-injection threshold). For
Figures 3.5 and 3.6, sex differences in mechanical threshold were analyzed using repeated
measures three-way ANOVA, with Sex and Drug analyzed as between-subject factors, and
Time analyzed as a within-subject factor. To assess the Drug by Sex interactions, linear
mixed models were used with random intercepts and time slopes for each animal. Pairwise
time points were individually analyzed using the mixed model approach to increase the
power to detect Sex by Drug interactions. Linear Mixed models were fit using the lme4
V1.1-15 package in R V3.4.3 (R software). The criterion for the level of significance was
set at P ≤ 0.05 (). All graphs were created using Prism 8 (GraphPad, La Jolla, CA).
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3.4 Rationale and Results
3.4.1 MOR and KOR, but not DOR opioid receptor signaling provide
postoperative endogenous analgesia
To determine which opioid receptors provide endogenous analgesia in the setting
of LS, we performed plantar incision, waited 21 days for mechanical hypersensitivity to
completely resolve, and then to these mice, termed PIM 21d mice, we intrathecally injected
opioid receptor subtype-selective antagonists.
Mu opioid receptor. As illustrated in Figure 3.1A, intrathecal administration of the
selective MOR antagonist CTOP in male PIM 21d mice dose-dependently reinstated
mechanical hypersensitivity as compared to saline (F (28,217) =9.43, p<0.0001). The
pronociceptive effect of CTOP was robust, peaking at 30 min (0.14  0.03g, 0.08  0.02g
at 1ng and 1000ng respectively), and lasted for at least 180 min. As illustrated in Figure
3.1B, area under the curve analysis (AUC 30-180min) illustrates concentration-dependent
effects of CTOP (F (4, 29) =41.3, p<0.0001). As illustrated in Figure 3.1C, conversion of
the 30 min timepointn data to %MPE yielded an ED50 value of 1.84 ng.
Delta opioid receptor. As illustrated in Figure 3.2A, this dose of naltrindole did not
change mechanical hypersensitivity in male PIM 21d mice (F (6,156) =2.01, p=0.07). We
then tested an alternative DOR antagonist (TIPP [Ψ] 1µg-10µg), and Fig 2B similarly no
effect on mechanical hypersensitivity (F (12,102) =0.35, p=0.97).
Kappa opioid receptor. We used either the prototypical KOR antagonist nor-BNI
or the shorter-acting and highly selective KOR antagonist LY24506302 due to its favorable
pharmacokinetic properties compared to nor-BNI (Munro et al., 2012; Rorick-Kehn et al.,
2014b). As illustrated in Figures 3.3A-B, the selective KOR antagonists nor-BNI (0.143

10µg) or LY2456302 (0.1-10µg) produced a dose-dependent reinstatement of mechanical
hypersensitivity compared to saline- (Nor-BNI, F (27,216) =3.73, p<0.0001 and
LY2456302, F (33,286) =5.63, p<0.0001, Fig. 3.3A, D). The effect on hyperalgesia of both
Drugs peaked at 3h (Nor-BNI, 0.19  0.06g and LY2456302, 0.30  0.04g) and lasted at
least 72h. As illustrated in Figures 3.3 C-D, AUC analysis (1-72h) yielded F values of (F
(3, 24) =12.90, p<0.0001) Nor-BNI and (F (3, 26) =20.37, p<0.0001) for LY2456302. As
illustrated in Figures 3.3 E-F, focus on the 3h timepoint yielded ED50 values of 0.87µg for
nor-BNI and 1.04µg for LY2456302.
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Figure 3.1. Spinal MOR blockade reinstates mechanical hypersensitivity in a dose
dependent manner.
The MOR selective antagonist CTOP was intrathecally (i.t.) administered 21d after plantar
incision in C57/Bl6 male mice. (A) Time course of mechanical hypersensitivity after CTOP
(1ng-1000ng) administration produces reinstatement of mechanical hypersensitivity in a
dose-dependent manner (n=8 per dose). (B) The area under the curve (AUC, 30-180 min)
illustrates the concentration-dependent actions of CTOP on mechanical hypersensitivity.
(C) Dose-response analysis of the data at 0.5h after injection revealed an ED50 of 1.84ng.
MPE: maximum possible effect. p<0.05 CTOP vs. vehicle. BL = baseline behavior prior
to drug administration.
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Figure 3.2. Spinal DOR selective antagonists do not reinstate mechanical
hypersensitivity.
DOR selective antagonists Naltrindole (A) and TIPP(Ψ) (B) were administered i.t. 21d after
plantar incision in C57Bl6 mice. Time course of mechanical hypersensitivity after
Naltrindole (1ug-10ug), and TIPP(Ψ) (1ug-10ug) administration show no significant
reinstatement of mechanical hypersensitivity (n=10-18 per dose Naltrindole p=0.07, n=68 per dose TIPP(Ψ), p=0.9). BL = baseline behavior prior to drug administration.
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Figure 3.3. Spinal KOR blockade reinstates mechanical hypersensitivity in a dosedependent manner.
The KOR selective antagonists Nor-BNI (A) and LY2456302 (B) were intrathecally (i.t.)
administered 21d after plantar incision in C5/Bl6 male mice. Time course of mechanical
hypersensitivity after Nor-BNI (0.1ug-10ug; n=5-10 per dose) and LY2456302 (0.1ug10ug; n=6-8 per dose) administration exhibited robust reinstatement of mechanical
hyperalgesia in a dose-dependent manner. (C-D) Area under the curve (Nor-BNI AUC,
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1-72h; LY AUC, 1-120h) illustrates the concentration-dependent actions of both drugs on
mechanical hypersensitivity. (E-F) Dose-response analysis of the data at 3h revealed an
ED50 of 0.87ug for Nor-BNI, and an ED50 of 1.04ug for LY2456302 for mechanical
hypersensitivity. MPE: maximum possible effect. p<0.05 Ly/Nor-BNI vs. vehicle. BL
= baseline behavior prior to drug administration.
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3.4.2 Spinal kappa opioid antagonism modulates latent nociceptive
sensitization in the dorsal horn
Our pharmacological behavior experiments demonstrated that spinally delivered
KOR antagonists produce reinstatement of hyperalgesia 21 days after surgical paw
incision. These findings suggest that similar to MOR, KORs exert tonic inhibition that
opposes pronociceptive signals within the spinal pathways, preserving LS within a state of
remission. Thus, to determine whether KOR activity reduces the cellular manifestations of
latent sensitization after incision, we evaluated the light-touch-evoked expression of
pERK, a well-recognized marker of central sensitization during pathological pain (Gao and
Ji, 2009; Ji et al., 2009), in the superficial (I-II) and deep laminae (III-V) of the dorsal horn.
We assessed immunohistochemical changes in pERK expression in the dorsal horn during
the peak of drug activity, 2h after LY or saline i.t. delivery. Intraplantar capsaicin was used
as a positive control as it activates C-afferent fibers markedly increasing the
phosphorylation of ERK in the superficial dorsal horn (Kawasaki et al., 2004). We
quantified the number of pERK-positive cells as a marker of activation of the nociceptive
sensitization pathway. We found that compared to controls, light-touch of the injured
hindpaw increased pERK cell profiles 21 days after plantar incision in the ipsilateral dorsal
horn (4.89 ± 0.48 vs. 0.77 ± 0.11, p<0.0001; 1.36 ± 0.22 vs. 0.22 ± 0.22, p=0.3) LY vs.
vehicle in the ipsilateral lam I-II and III-V respectively. (4.89 ± 0.48 vs. 1.52 ± 0.16) LY
ipsilateral vs. contralateral paw. F (3, 16) = 16.83, p<0.0001) 2 hours after KOR blockade
(Figure 3.4 B-E).
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Figure 3.4. KOR spinal blockade via LY2456302 increased light-touch evoked
positive pERK cells in the dorsal horn.
The number of positive pERK cell profiles in the dorsal horn (A) superficial (I-II) and deep
(III-V) lamina the Rexed is increased after intrathecal administration of (B) LY (10ug) and
(C) capsaicin (positive control) compared (D) to vehicle administration in 21d
postoperative male mice. (E-F) Histogram showing light touch-induced pERK-positive
cells are significantly higher in LY treated mice compared to controls in the side ipsilateral
to the injury (n=3-4, 4-5 slices per animal). p<0.05 LY vs. vehicle, # p<0.05 ipsilateral
vs. contralateral. Scale bar 100m. Figure (A) adapted from Corder et al, 2013.
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3.4.3 Postoperative endogenous KOR Analgesia is enhanced in female mice
As illustrated in Figures 3.5 and 3.6, plantar incision produced a robust decrease
in mechanical threshold on the paw ipsilateral but not contralateral to injury. The time
course of mechanical hypersensitivity did not significantly differ between male and female
mice (p>0.05) when tested at either the paw ipsilateral to injury (Fig 3.5.A-B and 3.6.A-B)
or contralateral to injury (Fig 3.5C-D and 3.6C-D). Thresholds returned to baseline by postoperative day 21 in each sex. These results are consistent with previous findings in mouse
incision models (Banik et al., 2006).
Postoperative patients exhibit sex differences in endogenous opioid inhibition of
pain (Fillingim and Gear, 2004). We previously reported that inverse agonist-induced
reinstatement of mechanical hyperalgesia and facial grimace in the CFA model of LS did
not differ between male and female mice (Corder et al., 2013); however, these studies were
limited to to a single dose of naltrexone which can interact with mu, delta, and kappa opioid
receptors. Therefore, we asked whether low or high doses of CTOP or LY2456302, as
determined by the dose-response curves in Figures 3.1 and 3.3, would yield sex differences
in mechanical thresholds after injection in PIM 21d male and female mice.
Mu opioid receptor. Our results in male mice demonstrated that both CTOP 100ng and
1000ng dose produced robust hyperalgesia in PIM 21d male mice (Figure 3.1A), which
were close to the maximum efficacy (Figure 3.1C). Thus, we selected 100ng for further
studies. As illustrated in Figure 3.5A, a high dose of CTOP (100ng) but not vehicle
produced robust hyperalgesia in PIM 21 male and female mice at the ipsilateral side (Main
Drug Effect F (1,90)= 57.25, p<0.0001; Time vs. Sex vs. Drug Interaction F (5,90)= 0.19,
p=0.96). As illustrated in Figure 3.5B, CTOP (100 ng) also produced a robust hyperalgesia
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at the contralateral side that did not differ between the sexes (Main Drug Effect F (1, 54)
=48.80, p<0.0001; Time vs. Sex vs. Drug Interaction F (5, 54)=0.87, p=0.50). As illustrated
in Figure 3.5C, AUC analysis confirmed that CTOP (100 ng)-induced reinstatement of
hyperalgesia did not differ between the sexes (F (3, 43) =0.90, p=0.78).
Since this relatively high dose of CTOP may have produced a floor effect that could
have masked a sex differences, we repeated this study using the lowest effective dose in
males (Figure 1). As illustrated in Figure 3.5D-F, low-dose CTOP reinstated hyperalgesia
(main Drug effect F (1,44) =4.40, p =0.04 ipsilateral; F (1,14) = 5.99, p=0.02 contralateral)
to a similar degree in male and female mice (Time vs. Sex vs. Drug Interaction F (5,220)
=0.24, p=0.94, Fig. 3.5B; Time vs Sex vs. Drug Interaction F (5,70) =0.34, p=0.88), AUC
F(3, 58) =0.08, p =0.1 (Figure 3.5.F).

53

Figure 3.5. Spinal MOR blockade reinstates mechanical hypersensitivity equally in
male and female mice.
(A-B) Time course of mechanical thresholds at baseline (BL), 1, 3, 5, 7,14 and 21-28 days
in male or female C57Bl/6 male, and then after intrathecal injection of CTOP at a dose of
100ng at the paw ipsilateral (A) or contralateral (B) to plantar incision. (C) Analysis of
area under the curve (AUC, 0.5-2h) illustrates that CTOP (100ng) reinstated mechanical
hypersensitivity at both the ipsilateral and contralateral hindpaws equally in males and
females. (D-E) Time course of mechanical thresholds at baseline (BL), 1, 3, 5, 7, 14 and
21-28 days in male or female C57Bl/6 male, and then after intrathecal injection of CTOP
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at a dose of 1ng at the paw ipsilateral (D) or contralateral (E) to plantar incision. (F)
Analysis of area under the curve (AUC, 0.5-2h) illustrates that CTOP (1.0ng) reinstated
mechanical hypersensitivity at both the ipsilateral and contralateral hindpaws equally in
males and females. n=4-10 per group. p<0.05 CTOP vs. vehicle. Data are represented
as mean +/- SEM.
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Kappa opioid receptor. Next, we investigated whether sex differences exist in endogenous
KOR-mediated inhibition of postoperative pain in our LS model. We chose not only the
prototypical KOR antagonist (inhibitor) Nor-BNI, but due to its delayed onset and
duration of action which can last up to four weeks (Horan et al., 1992; Munro et al., 2012),
we also selected the shorter-acting KOR antagonist LY24506302 due to its favorable
pharmacokinetic properties compared to nor-BNI (Rorick-Kehn et al., 2014a; Rorick-Kehn
et al., 2014b). As illustrated in Figure 3.6A-B, a relatively high dose of LY24506302
(10µg) reinstated mechanical hypersensitivity compared to saline in male and female mice
at the sides both ipsilateral (F (1, 21) = 21.80, p<0.0001) and contralateral (F (1, 21) =
14.44, p=0.001) to plantar incision. However, the degree of reinstatement did not differ
between the sexes (Time vs. Sex vs. Drug interaction F (8,168) = 0.13, p = 0.99, 5A; F
(8,168) = 0.25, p = 0.25, 5D), and this is further illustrated in Figure 3.6C by area under
the curve analysis across the 1 to 120 hr time points (F (3, 43) = 0.356, p=0.78).
Since this relatively high dose of LY24506302 may have produced a floor effect that
could have masked a sex difference, we repeated this study using a lower dose of 0.3 µg as
suggested by the dose-response curve in Figures 3.3D-F. As illustrated in Figure 3.6D,
LY2456302 (0.3 µg) reinstated hyperalgesia at the side ipsilateral to incision in both male
and female mice, and importantly to a greater extent in female mice (Bonferroni posthoc
test p<0.05). Figure 3.6E illustrates a smaller effect on the contralateral side that did not
differ between sexes. Further analysis in Figure 3.6F illustrates that female PIM 21d mice
exhibited greater mechanical hyperalgesia at the peak of LY-induced reinstatement at the
2-4h time points (Sex vs. Drug Interaction, Satterthwaite: p-value=0.041).
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Figure 3.6. LY2456302-induced reinstatement of mechanical hypersensitivity is
greater in females.
(A-B) Time course of mechanical thresholds at baseline (BL), 1, 3,5, 7, 14 and 21-28 days
in male or female C57Bl/6 male, and then after intrathecal injection of LY2456302 at a
dose of 10μg at the paw ipsilateral (A) or contralateral (B) to plantar incision. (C) Analysis
of area under the curve (AUC, 0.5-2h) illustrates that LY2456302 (10μg) reinstated
mechanical hypersensitivity at both the ipsilateral and contralateral hindpaws equally in
males and females. (D-E) Time course of mechanical thresholds at baseline (BL), 1, 3, 5,
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7, 14 and 21-28 days in male or female C57Bl/6male, and then after intrathecal injection
of LY2456302 at a dose of 0.3μg at the paw ipsilateral (D) or contralateral (E) to plantar
incision. (F) Analysis of area under the curve (AUC, 0.5-2h) illustrates that LY2456302
(0.3μg) reinstated mechanical hypersensitivity at both the ipsilateral and contralateral
hindpaws equally in males and females. n=6-8 per group. p<0.05 LY2456302 vs.
vehicle, #p<0.05 male vs. female. Data are represented as mean +/- SEM.
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3.4.4 Tonic KOR inhibition of dorsal horn neuron activity is enhanced in
female mice
We previously reported that MORCA inhibits long-lasting sensitization of dorsal
horn neurons induced by cutaneous inflammation (Corder et al., 2013). To begin to address
whether KOR inhibits neuronal activity as well, we evaluated light touch-evoked
expression of pERK in the superficial (I-II) and deep laminae (III-V) of the dorsal horn,
two hours after intrathecal administration of LY2456302 or saline in male and female mice,
21 days after either sham or plantar incision surgery. As illustrated in Figures 3.7A-B, DE, G-H, light touch was associated with only a small number of pERK-positive profiles in
sham controls that received LY2456302 or vehicle treated mice. By contrast, Figures 3.7C,
3.7F, and 3.7G illustrate that LY2456302 evoked a larger number of pERK+ profiles in
PIM 21d mice at both superficial lamina I-II (F (5,23) = 1.61, p<0.001) and deeper laminae
III-V (F (5,44) = 6.60, p=0.001). Importantly, LY2456302 was associated with
significantly more pERK+ profiles in laminae I-II in females as compared to males
(p<0.05). p-ERK can be expressed on neurons, astrocytes, and microglia (Ji et al., 2009).
To determine the cell type(s) that express pERK after LY2456302, we co-labelled with
NeuN, GFAP, and Iba1. As illustrated in Figure 3.8, confocal microscopy revealed that
pERK was expressed exclusively in NeuN-positive cells in laminae I–V of the dorsal horn
obtained from female (Figures 3.8A-U) or male (Figures 3.8A’-U’) mice.
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Figure 3.7. LY2456302-evoked pERK+ cells in the dorsal horn is greater in female
mice.
Representative photomicrographs of light touch-evoked pERK-immunoreactivity in L4
lumbar sections from (A-C) female or (D-F) male mice, 21 days after sham surgery plus
10µg LY2456302 (A, D), plantar incision plus vehicle (B, E), or plantar incision plus 10µg
LY2456302 (C, F). (G-H) Quantification of mean number of touch-evoked pERK+
profiles in lamina I-II (G) or lamina III-V (H). Data represent mean +/- SEM. ★p<0.05.
LY2456302 vs. vehicle and sham incision. *p<0.05 LY2456302 vs. shams. # p<0.05 n= 46 (5 slices per mouse). Scale bar: 100µm.
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Figure 3.8. Touch-evoked pERK in the dorsal horn is co-localized exclusively with
neurons.
To determine whether KOR blockade evoked pERK expression in neurons, microglia, or
astrocytes, we co-stained with NeuN, Iba1, or GFAP, respectively. Representative
transverse lumbar (L4) spinal cord sections (30μm) from postoperative-21d mice 2h after
intrathecal delivery of LY2456302 (10μg) and an ipsilateral light touch paw stimulation.
Sections from females were co-labelled with pERK (A, C, D, G, H, J, K, N, O, Q, R and
U), and either NeuN (B-C, E, G), GFAP (I-J, L, N), or Iba-1 (P-Q, S-U). DAPI (F-G, M-
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N, T-U). Sections from males were co-labelled with pERK (A’, C’, D’, G’, H’, J’, K’,
N’, O’,Q’, R’ and U’), and NeuN (B’-C’, E’,G’), GFAP (I’-J’, L’,N’), or Iba-1 (P’-Q’, S’U’). DAPI (F’-G’, M’-N’, T’-U’). Arrows indicate pERK co-labeling. Light microscopic
images in the left three columns were taken with a 10X objective, while confocal images
in the right four columns were taken with a 60x objective. Scale bars: 50 μm.
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3.5 Discussion
3.5.1

Tonic

MOR

activity

provides

long-lasting

inhibition

of

postoperative pain
Tissue injury induces latent pain sensitization (i.e., LS) that is mediated in part by
NMDA receptors, AMPA receptors, and adenylyl cyclase 1 signaling mechanisms in the
dorsal horn (Corder et al., 2013; Taylor et al., 2019). These pronociceptive mechanisms
are kept within remission by opposing pain inhibitory mechanisms (Solway et al., 2011;
Corder et al., 2013; Walwyn et al., 2016; Fu et al., 2019) that include MOR CA (Corder et
al., 2013; Walwyn et al., 2016). Evidence for the contribution of MOR comes in part from
behavioral pharmacology studies using MOR-selective inhibitors. For example, when
administered 21 days after the intraplantar injection of complete Freund’s adjuvant (after
the resolution of initial hyperalgesia), intrathecal administration of a single dose of CTOP
reinstated hyperalgesia (Corder et al., 2013). The current results not only extend these
findings to the plantar incision model of postoperative pain, but also demonstrate a doseresponse curve with an ED50 value of approximately 2 ng.
3.5.2 Spinal DORs do not provide long-lasting inhibition of postoperative pain
Selective DOR activation inhibits mechanical hypersensitivity associated with
injury (Scherrer et al., 2009; Gaveriaux-Ruff et al., 2011; Bardoni et al., 2014) either
through heterodimerization or synergistic interactions with MOR (Gomes et al., 2000;
Hurley and Hammond, 2000; Gendron et al., 2007; Al-Hasani and Bruchas, 2011) or via
autonomous mechanisms in distinct populations of spinal neurons, different than those that
express MOR (Wang et al., 2018). In contrast to these studies using exogenous application
of DOR agonists to inhibit early inflammatory pain, the current studies tested the
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hypothesis that endogenous activation of DOR inhibits the longer-lasting vulnerability to
inflammatory pain associated with LS. However, neither of the DOR antagonists that we
used, naltrindole nor TIPP[Ψ], significantly changed mechanical threshold when
administered during the remission phase of LS.
Our DOR results are not consistent with Walwyn and colleagues who reported that
subcutaneous administration of naltrindole reinstated hyperalgesia in a mouse CFA model
of LS, and that either intrathecal or subcutaneous naltrindole reinstated hyperalgesia in a
rat CFA model of LS (Walwyn et al., 2016). One possibility for the differences observed
in the latter study and ours is that we tested the animals at a later time point after DOR
administration. However, the reinstatement observed in the latter study was very shortlasting and induced at an earlier time point (15 min after i.t. administration) in both
experimental and control groups. Thus, confounders such as anxiety and sensitization of
the subjects from repeated pharmacological experiments in the same animal could not be
ruled out. Albeit, it is fundamentally interesting to speculate here that the plantar incision
model and the CFA model (Walwyn et al., 2016) could induce LS via different receptors
or mechanisms.
In summary, our data suggest that DOR inhibitors do not reinstate hyperalgesia,
and thus we conclude that spinal DORs do not provide long-lasting inhibition in our model
of postoperative latent pain sensitization. Since our studies were limited to the intrathecal
route of administration future studies are needed to investigate the role of endogenous
DORs expressed at peripheral terminals of primary afferent neurons (Scherrer et al., 2009)
or supraspinal sites involved in the descending inhibition of spinal transmission (Hurley
and Hammond, 2000).
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3.5.3 Tonic KOR activity provides long-lasting inhibition of postoperative pain
The current results demonstrate that the kappa receptor-selective inhibitors norBNI and LY2456302 dose-dependently reinstated behavioral signs of postoperative pain,
and LY2456302 increased the stimulus-evoked expression of pERK, a marker of central
sensitization, in dorsal horn neurons but not glia. Our results are consistent with and extend
previous studies that suggest a contribution of endogenous KOR to the inhibition of
hyperalgesia. For example, systemic administration of nor-BNI reinstated hyperalgesia
after paw incision performed under remifentanil in the mouse (Campillo et al., 2011)
Furthermore, Marvizon and colleagues reported that nor-BNI reinstated mechanical
hyperalgesia in the CFA model of LS (Walwyn et al., 2016). Prodynorphin deficient mice
also responded with reinstatement of mechanical hyperalgesia, consistent with the
hypothesis that, like MORCA, inflammation leads to constitutive activity at KOR (Walwyn
et al., 2016). Therefore, in the current studies of LS, we have been careful to describe norBNI and LY2456302 as KOR inhibitors, since we do not yet know whether their behavior
is indicative of inverse agonism and ligand-independent constitutive activity, or
antagonism and ligand-dependent activity. Albeit, our findings indicate that LS is
maintained in remission by tonic KOR activity at the dorsal horn.
In addition to the spinal sites of action suggested by our intrathecal injection
studies, peripheral and supraspinal sites may also contribute to endogenous KOR inhibition
of LS. Regarding peripheral sites, KOR is expressed in the nerve terminals of peptidergic
populations of primary afferent neurons arising from the skin, viscera, and synovial tissues,
and KOR signaling inhibits nociceptor sensitization and pain (Labuz et al., 2007; Cunha et
al., 2012; Moon et al., 2016; Snyder et al., 2018). A recent study indicated that peripherally-
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restricted KOR agonists markedly reduced mechanical hyperalgesia at the early
inflammatory phase of plantar incision (Snyder et al., 2018), implicating peripheral KOR
as a major modulator of acute postoperative pain. Regarding supraspinal sites,
microinjection of KOR agonists into the rostral ventral medulla activated descending
modulatory neurons to inhibit nociception (Hurley and Hammond, 2000; Schepers et al.,
2008b; Schepers et al., 2008a) . Furthermore, the current study (Fig 3.6.) demonstrated that
KOR inhibitors reinstate hyperalgesia not only at the side ipsilateral to injury but also at
the contralateral side, thus further implicating supraspinal modulation of LS as previously
proposed for MOR (Corder et al., 2013) and suggested by the current CTOP results (Fig
3.5).
KOR inhibitors produce not only hyperalgesia as in the current studies, but also
antihyperalgesia in other studies. For example, in rats primed with sumatriptan or morphine
infusion, delivery of KOR inhibitors in the central amygdala prevented acute stressinduced hyperalgesia. In these studies, the pronociceptive effects of KOR were elicited
from a descendent modulatory circuit from the right amygdala via MAPK signaling (Xie
et al., 2017). Furthermore, KOR in the central nucleus of the amygdala promotes behaviors
suggestive of disinhibition, aversiveness, anxiety (Narita et al., 2006) and pain facilitation
(Navratilova et al., 2018). Thus, we propose that the direction of effect depends on the site
of modulation, with KOR activation at the central terminals of primary afferent and
intrinsic dorsal horn neurons leading to pain inhibition, while KOR activation at certain
brain sites seems to cause pain.
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3.5.4 Sex differences in postoperative pain: evidence and controversies
Numerous studies have investigated sex differences in nociception (Greenspan et
al., 2007; Hendrich et al., 2012) and endogenous opioid pain modulation (Tambeli et al.,
2001; Fillingim and Gear, 2004; Fillingim et al., 2009). As described previously (Banik et
al., 2006), we found that male and female mice presented similar mechanical thresholds
and responded to plantar incision with a mechanical hyperalgesia of similar intensity and
time course. However, these results are in contrast with other preclinical studies that
indicate that females present lower mechanical nociceptive thresholds (Barrett et al.,
2002a; Rasakham and Liu-Chen, 2011; Hendrich et al., 2012; Chartoff and Mavrikaki,
2015) and take longer to recover from injury than males (Vacca et al., 2014). Furthermore,
women commonly report more severe pain than men (Greenspan et al., 2007; Tsang et al.,
2008; Fillingim et al., 2009) and are more predisposed to develop persistent postoperative
pain (Kehlet et al., 2006). Moreover, human laboratory indicate that females present lower
mechanical nociceptive thresholds and take longer to recover from injury than males (Riley
et al., 1998; Fillingim and Gear, 2004).
3.5.5 Sex differences in KOR (but not MOR) inhibition of latent
postoperative pain
Our observations indicate that intrathecal administration of either low or high doses
of CTOP equally reinstated mechanical hypersensitivity in PIM 21d male and female mice.
By contrast, we found that intrathecal administration of a low dose of the KOR inhibitor
LY2456302 produced a significantly more pronounced hyperalgesia and pERK activation
in the dorsal horn of female mice as compared to male mice. The inability to demonstrate
this sex difference with a higher dose of LY2456302 is likely due to a floor effect
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associated with low mechanical thresholds. Although the sex differences following low
dose LY2456302 were of small magnitude, they were statistically significant, and thus
support our conclusion that tonic endogenous KOR-mediated inhibition of postoperative
pain is more pronounced in females.
Consistent with our findings related to endogenous KOR inhibition of postoperative
pain, clinical studies suggest a sexual dimorphism in response to exogenous
pharmacological KOR agonists in the management of postoperative pain (Pande et al.,
1996b; Pande et al., 1996a). For example, clinical trials using mixed-action MOR/KOR
ligands and self-reported pain scales revealed that KOR agonism yields enhanced
postoperative analgesia in women following third molar extraction (Gear et al., 1996a;
Gear et al., 1996b, 1999). However, the literature of sex differences in the analgesic or
antihyperalgesic actions of pharmacological agonists with selectivity at KOR is
inconsistent or even contradictory. On one hand, KOR agonists can exert greater
antinoception in male rodents (Barrett et al., 2002b; Terner et al., 2003a; Terner et al.,
2003b; Sternberg et al., 2004), while others suggest that KOR agonists can exert greater
antinociception in females (Mogil et al., 2003; Lomas et al., 2007; Robinson et al., 2016).
Similar mixed effects have been reported in rodent models of inflammatory pain: KOR
agonists can exert greater antihyperalgesia in males as compared to females (Rasakham
and Liu-Chen, 2011; Auh and Ro, 2012), or greater antihyperalgesia and inhibition of
spinal Fos expression in females as compared to males (Bereiter, 2001; Clemente et al.,
2004; Lawson et al., 2010).
The mechanisms by which endogenous KOR modulates postoperative pain in a
sex-dependent manner remains to be answered. Sex differences in KOR pharmacology
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have been attributed to gonadal hormones or genetic factors (Mogil et al., 2003; Rasakham
and Liu-Chen, 2011). Sex differences in KOR-mediated mechanical and heat
antinociception may be mediated by estrogens (Lawson et al., 2010; Robinson et al., 2016)
and progesterone (Sternberg et al., 2004). Estrogen levels regulate KOR gene expression
and density (Harris and Drake, 2001; Harris et al., 2004; Kren et al., 2008; Lawson et al.,
2010). Moreover, spinal estrogen signaling regulates the expression of MOR/KOR
heterodimers (Liu et al., 2011), of which expression is higher in proestrus females
(Chakrabarti et al., 2010). In contrast, other studies attribute the sex differences in KOR
analgesia to the protective effect of androgen hormones, as testosterone negatively
regulates KOR function (van Haaren et al., 2000; Rasakham and Liu-Chen, 2011; Macedo
et al., 2016).
Genetics also likely contributes to sex differences in KOR analgesia. For example,
the XY chromosome is positively associated with the expression of the dynorphin gene
(Chen et al., 2009) and heat threshold alterations in response to KOR agonists (Gioiosa et
al., 2008). In the human experimental setting, a greater response to KOR mixed-agonists
on heat and ischemic pain was observed in a subset of redheaded and fair skinned women
related to polymorphisms on the melanocortin-1-receptor gene (MC1R) (Mogil et al., 2003;
Fillingim and Gear, 2004). Further studies are needed to determine the contribution of
hormonal, neurochemical, and genetic factors to sex differences in endogenous KOR
inhibition of latent postoperative analgesia.
In summary, our results indicate that surgical incision leads to long-lasting, LS of
dorsal horn neurons that is tonically opposed by prolonged activation of MOR and KOR
signaling in the spinal dorsal horn. We found a modest, but significant sex difference in
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neuron-dependent KOR-mediated postoperative endogenous analgesia. Considering that
LS represents a period of susceptibility for chronic pain, sex differences in endogenous
opioid analgesia may shed some light on potential central mechanisms involved in the
higher predisposition of females for persistent pain states. Indeed, failure of MOR or KOR
signaling could lead to persistent postsurgical pain. A better understanding of sexdependent endogenous pain inhibition by spinal KOR is essential for the development of
new KOR-based pharmacotherapies that target pain and addiction.

Copyright © Lilian Custodio 2019
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CHAPTER 4. Kappa Opioid Receptor Targets Adenylyl Cyclase 1, PKA and Epac
to Maintain Latent Postoperative Pain Sensitization within a State of Remission
4.1 Abstract
We previously reported that endogenous kappa opioid receptor (KOR) activity
tonically inhibits latent sensitization (LS) in a murine plantar incision model of
postoperative pain for at least 3 weeks after surgical incision. We now report that
intrathecal injection of the KOR selective agent, LY2456302 (CERC 501, 10µg, i.t.),
restored hyperalgesia when administered much longer, 13 months, after surgical incision.
We next determined whether endogenous KOR maintains latent postoperative pain by
inhibiting cAMP-dependent pathways, with a focus on adenylyl cyclase isoform-1 (AC1)
and its two downstream receptors, protein kinase A (PKA) and exchange protein activated
by cAMP (Epac). We used AC1 knock-out (KO) mice and pharmacological inhibitors of
AC1 (NB001, 1.5µg i.t.), PKA (H89, 10nmol) and Epac1/2 (ESI-09, 10µg i.t.), and
measured mechanical stimulus-evoked behaviors and immunoreactivity of phosphorylated
extracellular signal-regulated kinase (pERK), a marker of LS-associated sensitization of
spinal dorsal horn neurons. Postoperative hyperalgesia was attenuated in AC1 KO male
mice. Moreover, AC1 gene deletion and NB001 precluded LY2456302-evoked
reinstatement of hyperalgesia in both male and female mice. Furthermore, H89 prevented
LY2456302-evoked reinstatement of mechanical hyperalgesia in male but not female mice,
while ESI-09 reversed hyperalgesia in both sexes. We conclude that sustained KOR
signaling inhibits spinal AC1-dependent mechanisms that drive postoperative LS in a sexdependent manner.
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4.2 Introduction
Persistent postoperative pain develops in millions of patients that undergo a variety
of surgical procedures (Kehlet et al., 2006). Opioids remain the mainstay analgesics of
acute postoperative pain; however, prolonged opioid therapy may lead to life-threating
adverse effects, tolerance, dependence, addiction liability, and paradoxical pain
exacerbation. A better understanding of the cellular mechanisms that drive persistent pain
states, and opposing endogenous analgesia provided by opioid receptor signaling, may lead
to the development of novel treatments for chronic postoperative pain. To this end, we
employed a murine model of chronic postoperative pain that involves plantar incision of
the hindpaw, followed by a waiting period of multiple weeks. Although hyperalgesia has
resolved, what remains is a silent, long-lasting sensitization of nociceptive neurons in the
dorsal horn (Solway et al., 2011; Taylor and Corder, 2014). This “latent sensitization (LS)”
is masked by compensatory activity of multiple pain-inhibitory G-protein coupled
receptors including μ-opioid receptor constitutive activity (MOR CA (Corder et al., 2013),
the kappa opioid receptor (KOR) [Custodio et al, submitted], and the neuropeptide Y
(NPY) Y1 receptor (Fu et al., 2019). We previously reported that MOR CA and Y1R
suppress an LS that is driven by an NMDA receptor adenylyl cyclase-1 (AC1)
signaling mechanism after chronic inflammation (Corder et al., 2013; Fu et al., 2019).
For several reasons, we hypothesized that AC1 may also mediate the LS that is
masked by KOR. First, KOR is an inhibitory G- protein-coupled receptor (GPCR), and as
such inhibits the activity of the adenylyl cyclases (AC) (Childers et al., 1992). Adenylyl
cyclase 1 (AC1) is a Ca+2 - activated protein that acts as a key modulator for the induction
of pathological pain in the CNS (Wu et al., 1995; Liauw et al., 2005; Wei et al., 2006;
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Zhuo, 2012). It couples the intracellular Ca+2 derived from NMDAR activation to
downstream activation of an array of downstream proteins and kinases (Zhuo, 2012).
Similar to MOR, persistent activation of KOR by an exogenous drug can also lead to an
AC “overshoot” (Avidor-Reiss et al., 1997; Nakagawa et al., 1999).
AC1 – cAMP signaling activates multiple downstream targets, including the
canonical protein kinase A (PKA) and an alternative pathway via Epac protein family
(Cheng et al., 2008). Epacs (Epac, isoform 1 and Epac, isoform 2) act as guanine
nucleotide exchange factors for small GTPases (de Rooij et al., 1998; Bos, 2003),
activating downstream PKC dependent pathways (Griffin, 2005; Hucho et al., 2005). Both
PKA and Epac isoforms have been implicated in the development of persistent
hyperalgesia after inflammation or tissue injury (Wang et al., 2013; Gu et al., 2016;
Singhmar et al., 2016; Matsuda et al., 2017; Singhmar et al., 2018).
The current studies were designed to test the hypothesis that surgical incision
establishes a long-lasting activation of KOR signaling that masks LS, in part through tonic
inhibition of pronociceptive AC1 signaling to downstream cAMP target proteins: protein
kinase A (PKA) and/or exchange protein activated by cAMP (Epac). To address this
hypothesis, we performed plantar incision in male and female mice, waited for behavioral
signs of hyperalgesia to resolve (21 days), and targeted spinal KOR, AC1, and cAMP
receptors with the intrathecal delivery of pharmacological antagonists (and in the case of
AC1, we also used AC1-/- mice), and then evaluated behavioral signs of hyperalgesia and
spinal nociceptive sensitization. The latter was assessed by the immunohistochemical
expression of the phosphorylated extracellular-signaling kinase (pERK) in the dorsal horn.

73

4.3 Materials and Methods
4.3.1 Animals
Male and female mice, 8-12 week of age were obtained from commercial sources
(C57Bl/6, Charles Rivers Laboratories) or bred in-house (adcy1 -/- = AC1 knockout and
wild-type littermate AC1+/+ controls, originally provided as a gift from Dan Storm,
University of Washington). Genotype was confirmed by tail-snip PCR before the beginning
of the studies. Animals were housed in a temperature-controlled room on a 14:10-hr
light/dark cycle and were provided food and water ad libitum. All animal use protocols
were approved by the IACUC at the University of Kentucky. All procedures were
approved by the Institutional Animal Care and Use Committee at the University of
Kentucky protocol (#2017-2768), in accordance with American Veterinary Medical
Association guidelines. Efforts were made to reduce the number of animals and their
suffering. Mice were acclimated to the colony housing room for at least 4 days, and then
handled for 4 days for 5 minutes prior to the initiation of the experiments.
4.3.2 Plantar Incision Model of Postoperative Pain (PIM)
Post-operative pain was induced by longitudinal incision of the plantaris muscle, as
previously described (Pogatzki and Raja, 2003; Jang et al., 2011). Under isoflurane
anesthesia (5% induction and 1.5-2% maintenance, via a nose cone) and antisepsis of the
left hind paw with Chlorascrub® then alcohol, a #11 scalpel blade was used to perform a
5mm through the skin and fascia using, beginning 2mm from the proximal edge of the heel
extending towards the digits. The underlying muscle was raised with a curved forceps,
extended 4 mm and incised longitudinally, leaving the origin and insertion of the muscle
intact. The overlying skin was closed with synthetic 5-0 sutures (PDS*II, Ethicon),
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followed by application of antibiotic ointment was applied. Surgery was typically
completed within 5-10min. Sutures were removed on the post-operative day 10. Sham
controls received anesthesia but no surgical incision.
4.3.3 Direct Intrathecal (i.t.) Drug Delivery
As previously described (Fairbanks, 2003), non-anaesthetized mice were lightly
restrained in a towel, and a 30G x1/2 needle (Becton Dickinson) attached to a 25-ul
Hamilton micro syringe, was inserted into the subarachnoid space between the L5/L6
vertebrae. The needle was angled about 30-45 degrees with the horizontal plane and
slightly advanced until reflexive tail flick was confirmed, then 5 µl of drug or vehicle was
slowly administered. The needle was held in place for 30sec, to ensure the solution fully
enters the spinal canal, withdrawn, and then the mouse was returned to its testing chamber.
4.3.4 Drug Dosing
We administered 5ul of the following drugs via intrathecal route at 21 postoperative
day mice: the compound LY2456302 (gift from NIDA Drug Supply Program) 10μg
(Rorick-Kehn et al., 2014a; Rorick-Kehn et al., 2014b) was dissolved in ddH20 and
sonicated at 30°C for 30minutes until complete homogenization of the drug was achieved.
LY2456302 (Med Chem Express) 10μg was dissolved in 1:1:8 (EtOH / Chremophor
(Sigma-Aldrich) / Saline) and injected at a dose of 10μg. Other drugs dissolved in saline
were NB001 1.5μg (Tocris); 6Bnz-cAMP 10nmol (BioLog); H89 10nmol (Tocris); 8-CPT
3nmol (BioLog). ESI-09 10μg (Almahariq et al., 2013; Chen et al., 2013) (gift from Jia
Zhuo, University of Texas Medical Branch) was dissolved in 1:1:8 (EtOH / Chremophor /
Saline). Dose-response studies previously performed in our laboratory informed our dose
of LY2456302 (Custodio et al, submitted), NB001 were determined based on (Corder et
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al., 2013), 6Bnz-cAMP, H89, 8-CPT, and ESI-09 (Fu et al., 2019). Control animals for the
behavioral assays received 5μl (i.t.) of the vehicle (sterile saline or 1:1:8 (EtOH /
Chremophor / Saline). All compounds were injected i.t. at least 3 weeks post-operatively,
after mechanical thresholds had returned to baseline levels. Some animals from figures
4.1A and 4.1C, 4.2A-D, 4.5A-D, and 4.7A-D were tested in a cross-over design receiving
saline or drug a week after the first inthratecal injection. Animals were matched to
experimental groups by a different investigator.
4.3.5 Mechanical Hyperalgesia Testing
All animals were acclimated in a temperature and light controlled room within
individual Plexiglas boxes placed on the top of a stainless-steel mesh platform for 30 to 60
min before behavioral testing. Mechanical hypersensitivity thresholds were assessed using
an incremental series of 8 von Frey filaments (Stoelting, Illinois) of logarithmic stiffness
(approximately 0.008-6 grams). The 50% withdrawal threshold was determined using an
up-down method (Chaplan et al., 1994). Each filament was applied perpendicular to the
surface of the skin just lateral to the incision site with enough force to cause a slight bending
of the filament. A positive response was defined by a rapid withdrawal of the paw within
5 seconds. Using the up-down method (Chaplan et al., 1994), the gram forces were
logarithmically converted into 50% of mechanical thresholds. This test was performed by
an observer blind to treatment at baseline up to 21 days post-PIM to confirm the
development of mechanical allodynia and assess the reinstatement of hyperalgesia three
weeks after surgery. Animals were assigned to experimental groups in all studies by a
different investigator than the examiner that remained blinded until the end of all
experiments.
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4.3.6 Phosphorylated Extracellular Signal-Regulated Kinase (pERK)
Stimulation
At 21 days after surgery mice received either vehicle or LY2456302 (10µg). Two
hours after injection, mice were lightly anesthetized with isoflurane (1.5%), and the ventral
surface of the ipsilateral hindpaw was mechanically stimulated with gentle 2-second stroke
with a cotton swab from heel to toe. This was repeated every 5s for 5min. After an
additional 5 min pause, mice were deeply anesthetized with isoflurane and transcardially
perfused with cold 0.01M phosphate buffer saline (PBS, Fischer Scientific) /heparin buffer
(10,000 USP units/L), followed by 10% phosphate formalin buffer. Lumbar spinal cords
were harvested and post-fixed in the same fixative overnight at 4 oC, and then cryoprotected
with 30%sucrose until total submersion (1-3 days).
4.3.7 Histology and Immunohistochemistry
Transverse sections (30μm) from L4 were obtained on a sliding microtome (Leica,
SM 2000R). A series of non-consecutive sections was washed in 0.01M PBS, blocked in
3% normal serum (goat or donkey; Gemini Bioproducts), containing 0.3% Triton X-100
(Sigma Aldrich) in 0.01M PBS for 1h, and then incubated with primary rabbit antibody
anti-phosphorylated-ERK ½ antiserum (1:800, Cell Signaling) at 4 oC for 36 hours on a
shaker. Sections were washed in 0.01M PBS and incubated with secondary goat anti-rabbit
Alexa Fluor 568 conjugated antibody (1:1000, Invitrogen) for 1h. The sections were
washed in 0.01M phosphate buffer, mounted and cover slipped with mounting medium
with DAPI (Vectashield, Vector laboratory).
Five good quality sections from spinal cord segments L4 per animal, in part were
randomly selected from each subject for pERK analyses. The number of pERK-positive
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cells on Rexed laminae I and II, and III-V were counted by a blinded examiner. All images
were captured with a Nikon TE-2000 microscope equipped with NIS-Elements AR 4.13.05
(Nikon), and the analyses performed with NIS-Elements Software AR analysis 4.13.05
Software offline (Nikon).
4.3.8 Statistical Analysis
Data was entered into Prism software (version 8.0, GraphPad, La Jolla, CA). All
data are presented as mean values with the corresponding standard error (mean ± SEM).
Two-way ANOVA repeated measures (RM) was generated to analyze differences in means
among groups over time. Drugs and doses were group factors and time was a repeated
measure. If a significant interaction was found, ANOVA was followed by Bonferroni posthoc analyses. Three-way ANOVA repeated measures was used to determine effects of sex
and treatment overtime as appropriate.

Area under the curve (AUC) or integrated

thresholds was plotted using the trapezoidal method and analyzed using ordinary two-way
ANOVA followed by Bonferroni. Statistical significance was set at p<0.05 (Tables 4.1 to
4.3).
4.3.9 Experimental blinding procedures
All the behavioral and immunofluorescence assays were conducted by the same
investigator (Lilian Custodio) who was blinded to the experimental groups and drugs
during all experiments. All the drugs and vehicles were prepared and disposed into
identical tubes and volume. The animals were allocated to the experimental groups by a
different examiner (Diogo dos Santos, Renee Donahue or Liping Zhang) who performed
the tube coding using a letter system. For the Epac and PKA studies due to the different
appearance (color) of the drugs and vehicles used that prevents an entirely blind procedure,
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the animals were allocated in the experimental groups and injected by a different examiner
(Diogo dos Santos or Renee Donahue after being acclimated to the animals). After the
completion of the experiment and data plotting in an excel sheet, the code was handled to
the examiner and the data analyzed. For the pERK experiments, to ensure blinding, the
animals were randomly handled to the experimenter by a colleague for injections and paw
stimulation. After completion of the experiment, the investigator was unblinded for the
groups.
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Table 4.1 Statistics for Figures 4.1 and 4.2.
Measure

Figure

RM Two-way ANOVA
Drug: F1,10 = 23.23, p=0.0007

Mechanical

Figure 4.1A
(males)

Thresholds

Time: F4.87,48.72 = 22.13, p=0.001
Drug vs Time: F11,110 = 9.40, p<0.0001
Drug: F1,13 = 22.60, p=0.0004

Figure 4.1B
(males)

Time: F11,143 = 23.38, p<0.0001
Drug vs Time: F11,143 = 5.72, p<0.0001
Drug: F1,13 = 6.41, p=0.02

Figure 4.1C
(males)

Time: F11,143 = 31.69 p<0.0001
Drug vs Time: F11,143= 3.54, p=0.0002
Genotype: F1,33 = 8.15, p=0.007

Figure 4.2A

Time: F3.31,109.4 = 178.2, p<0.0001

(males and
females)

Genotype vs Time: F5,165 = 3.29, p=0.007
Genotype: F1,16 = 4.77, p=0.04

Figure 4.2B
(males)

Time: F3.29,52.77 = 93.56, p<0.0001
Genotype vs Time: F5,80 = 3.69, p=0.004
Genotype: F1,15 = 3.24, p=0.09

Figure 4.2C
(females)

Time: F2.56, 38. 51 = 81.56, p<0.0001
Genotype vs Time: F5,75 = 0.83, p=0.52
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Table 4.2 Statistics for Figures 4.2 to 4.8
Measures

RM Two-way ANOVA
Males and Females

Mechanical
Thresholds

Figure Group:
2A

F3,52 = 14.76
p<0.0001

Males
Figure
2B

Group:
F3,24 =5.08
p=0.007

Females
Figure
2C

F3,24 =10.38
p=0.0001

Time:

Time:

Time:

F3.80,197.8=

F2.56,61.62=

F4.76,114.4=

18.82

8.68

10.51

p<0.0001

p=0.0002

p<0.0001

Group x

Group x

Group x

Time:

Time:

Time:

F27,46=

F27,216=

F27,216=

6.25

4.15

3.12

p<0.0001

p<0.0001

p<0.0001

Figure Group:
3A

Group:

F3,27=3.44
p=0.03

_

Time:
F3.64,98.36=
91.44
p<0.0001
Group x
Time:
F18,162 =
5.00
p<0.001

81

_

Table 4.2 Statistics for Figures 4.2 to 4.8 (continued).
Figure
Mechanical

5A

Thresholds

Figure
6A

Group:
F2,52= 4.44
p=0.01

Figure
5B

Group:
F2,24 =5.24
p=0.01

Figure
5C

Group:
F2,25 =0.58
p=0.56

Time:

Time:

Time:

F2.76,142.8=

F2.77,66.62=

F2.61,65.36=

19.86

13.78

5.94

p<0.0001

p<0.0001

p<0.0001

Group x

Group x

Group x

Time:

Time:

Time:

F6,156=

F6, 72=

F6,75=

3.93

3. 58

1.03 p=0.41

p=0.001

p=0.003

Group:
F3,44= 10.51
p<0.0001

Figure
6B

Group:
F3,20= 4.37
p<0.0001

Figure
6C

Group:
F3,20 = 7.29
p=0.001

Time:

Time:

Time:

F6,264=

F6,120=

F6,120=

169.3

86.10

95.05

p<0.0001

p<0.0001

p<0.0001

Group x

Group x

Group x

Time:

Time:

Time:

F18,264=

F18,120=

F18,120=

6.73

2.76

4.99

p<0.0001

p=0.0005

p<0.0001
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Table 4.2 Statistics for Figures 4.2 to 4.8 (continued).
Figure
Mechanical

7A

Thresholds

Figure
8A

Group:
F2,33= 6.56
p=0.004

Figure
7B

Group:
F2,18 =4.85
p=0.02

Figure
7C

Group:
F2,15 =2.95
p=0.08

Time:

Time:

Time:

F2.83,93.45=

F2.29,41.39=

F2.49,37.36=

19.61

10.45

9.13

p<0.0001

p<0.0001

p=0.0003

Group x

Group x

Group x

Time:

Time:

Time:

F6,99=

F6, 54=

F6,45=

5.27

3.01

3.60

p<0.0001

p=0.01

p=0.005

Group:
F3,44= 4.53
p=0.007

Figure
8B

Group:
F3,20= 2.98
p=0.05

Figure
8C

Group:
F3,20 = 2.13
p=0.12

Time:

Time:

Time:

F6,264=

F6,120=

F6,120=

154.0

94.45

63.67

p<0.0001

p<0.0001

p<0.0001

Group x

Group x

Group x

Time:

Time:

Time:

F18,264=

F18,120=

F18,120=

5.23

3.99

2.21

p<0.0001

p=0.0005

p=0.005
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Table 4.3 Area under the curve (AUC) analyses
Measure

Figure

Mechanical

Figure 4.2D
(males and females)

Thresholds

Area Under the Curve (AUC)
Sex: F1,48 = 0.01, p=0.89
Drug: F3,48 = 26.34, p<0.0001
Sex x Drug: F3,48 = 0.29, p=0.82

Figure 4.3B
(males and females)

Sex: F1,12 = 1.06, p=0.32
Drug: F1,12 = 16.59, p<0.0001
Sex x Drug: F3,48 = 0.05, p=0.82

Figure 4.5D
(males and females)

Sex: F1,33 = 5.30, p=0.02
Drug: F1,33 = 9.29, p=0.004
Sex x Drug: F1, 33 = 2.59, p=0.11

Figure 4.6D
(males and females)

Sex: F3,40 = 1.14, p=0.29
Group (Drug): F1,40 = 15.62, p<0.0001
Sex x Group: F3,40 = 0.95, p=0.42

Figure 4.7D
(males and females)

Sex: F1,20 = 2.13, p=0.15
Drug: F1,20 = 25.31, p<0.0001
Sex x Drug: F1,20 = 0.28, p=0.59

Figure 4.8D
(males and females)

Sex: F1,40 = 1.58, p=0.21
Group: F1,40 = 8.78, p=0.0001
Sex x Group: F3,40 = 1.66 p=0.18
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Table 4.3 Area under the curve (AUC) analyses (continued)
#pERK

Figure 4.4I

+cells

(males and females)
Lam I-V
Figure 4.4J
(males and females)
Lam I-II, III-V
Figure 4.4K
(males vs. females)
Lam I-V

Figure 4.4L
(males and females)
Lam I-II, III-V

Genotype: F1,28 = 16.46, p=0.0004
Region: F1,28 = 35.35, p<0.0001
Genotype vs Region: F1,28 = 14.35, p=0.0007
Genotype: F1,56 = 25.23, p<0.0001
Region: F3,56 = 37.86, p<0.0001
Genotype vs Region: F3,56 = 11.10, p<0.0001
Genotype: F1,12 = 16.33, p=0.001
Group (Sex vs region): F1,12 = 0.48, p=0.50
Genotype vs Group: F1, 12 = 0. 75, p=0.40
Region: F1,24 = 26.11, p<0.0001
Group (Sex vs genotype): F3,24 = 7.26, p=0.001
Region vs Group: F3,24 = 2.20, p=0.11
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Table 4.4 Three-way ANOVA analyses
Measure

RM Three-way ANOVA
(treatment x sex x drug)
Drug: F1,33 = 4.42, p=0.04

Mechanical

Figures 5B-C

Thresholds

(males and
females)

Time: F2.563, 84.59= 19.17, p<0.0001
Sex: F1,33 = 4.47, p=0.04
Drug vs Time: F3,99 = 4.53, p=0.005
Drug vs Sex: F1,33 = 2.01, p=0.16
Time vs Sex: F5,165 = 1.36, p=0.24
Time vs Sex vs Drug: F3,99 = 0.69, p=0.55
Drug: F1,20 = 7.84, p=0.01

Figure 7B-C
(males and
females)

Time: F2.65,52.99 = 29.82, p<0.0001
Sex: F1,20 = 1.80, p=0.19
Drug vs Time: F3,60 = 10.81, p<0.0001
Drug vs Sex: F1,20 = 0.16, p=0.69
Time vs Sex: F3,60 = 0.41, p=0.74
Time vs Sex vs Drug: F3,60 = 1.43, p=0.24
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4.4 Rationale and Results
4.4.1 Kappa-opioid receptors signal inhibit LS for at least 1 year after surgery
Our laboratory demonstrated that repeated intrathecal (i.t.) and systemic delivery
of the inverse agonist / non-selective opioid receptor antagonist, naltrexone, reinstated
hyperalgesia when administered a few months after intraplantar complete Freund’s
adjuvant (CFA) administration (Corder et al., 2013). Ongoing studies also indicates that
naltrexone reinstates mechanical hypersensitivity up to 1 year after plantar incision (dos
Santos, unpublished observations). As discussed at Chapter 3, mechanical hypersensitivity
persists up to 14 to 21 days after surgical incision of the hindpaw. We demonstrated that
MOR and KOR are the opioid receptor systems involved in the masking of LS. To
determine whether tonic KOR signaling also persists for such a long time beyond tissue
healing, we performed the plantar incision model (PIM), waited for the resolution of
mechanical hypersensitivity, and then intrathecally administered a KOR selective
antagonist (LY2456302) 21 days, 6 months and 13 months after surgery.
As illustrated in Figure 4.1, we found that LY2456302, but not vehicle, reinstated
mechanical hyperalgesia when administered at either 21 days F (11, 110) = 9.40,
p=0.0001), 6 months F (11, 143) = 5.72, p<0.0001) or 13 months F (11, 143) = 3.54,
p=0.0002, Table 4.1) after surgery. Our findings indicate that LS and opposing KOR
signaling persist for over a year after surgery.
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Figure 4.1. Endogenous kappa opioid inhibition of LS persists at least 13 months after
surgical incision.
Mechanical thresholds at baseline (BL), 2 days, and (A) 21 days, (B) 6 months, (C) up to
13 months after plantar incision in male C57Bl/6 mice. Intrathecal administration of
selective KOR antagonist LY2456302 (10µg), reinstated mechanical hypersensitivity
when given (A) 21 days, (B) 6 months, (C) up to 13 months after PIM (n=6-8). BL =
baseline behavior prior to drug administration. Data represented as mean +/- SEM.
 p<0.05. Bonferroni’s post-hoc tests following repeated measures of 2-way ANOVA.
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4.4.2 Prolonged kappa opioid receptor signaling silences behavioral and
neuronal signs of postoperative LS via inhibition of adenylyl cyclase, isoform
1 (AC1)
We investigated whether prolonged KOR signaling opposes LS via inhibition of
AC1. To answer this question, we used two approaches, an AC1 inhibitor, and AC1 -/mutant mice. Genetic and pharmacological interruption of AC1 does not change transient
nociception in uninjured animals (Wei et al., 2002), but prevents CFA-induced
hyperalgesia (Wei et al., 2002; Wang et al., 2011; Corder et al., 2013), and latent
sensitization (Corder et al., 2013; Fu et al., 2019). To test the hypothesis that KOR inhibits
AC1 to maintain latent postoperative pain sensitization in remission, we evaluated
LY2456302 (10µg)-induced reinstatement of hyperalgesia in AC1 knock out mice and
after inthratecal (i.t.) administration of the AC1 inhibitor, tested 21 days after plantar
incision.
As illustrated in Figure 4.2, AC1 KO mice and their wild-type controls exhibited
similar baseline mechanical thresholds, regardless of sex. After incision, the time course
of hyperalgesia differs across strain and sex. In males, post-incisional hyperalgesia in AC1
knockouts resolved faster than wild-type mice (F (5, 165) = 3.29; p=0.007, Table 4.1,
Figure 4.2A). However, when stratified by sex, AC1 KO accelerates the recovery of
hyperalgesia in male (F (5, 80) = 3.69; p=0.004, Table 4.1, Figure 4.2B), but not female
mice (F (5, 75) = 0.83; p=0.52, Table 4.1, Figure 4.2C). Moreover, AC1 gene deletion
abolished reinstatement of hyperalgesia induced by KOR antagonist in wild-type animals
(F (27, 468) = 6.25; p<0.0001, Figure 4.2A) of either sex (F (27, 216) = 4.15; p<0.0001 for
males, fig. 4.2B; F (27, 216) = 3.12; p<0.0001 for females, Table 4.2, Figure 4.2C).
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Integrated analyses over the 1-48h timepoints further illustrates that LY2456302-induced
reinstatement of hyperalgesia is different between the strains (drug vs genotype, F (3, 48)
= 26.34, p < 0.0001, Table 4.3, Figure 4.2D).
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Figure 4.2. AC-1 gene deletion precludes KOR antagonist-induced postoperative
hyperalgesia.
(A-C) Mechanical thresholds at baseline (BL), 1, 4, 7, and 21 days after plantar incision in
C57Bl/6 and AC1 KO. Gene deletion of AC1 accelerates the recovery of mechanical
thresholds after surgery in male (B), but not female mice (C). AC1 gene deletion prevented
LY2456302 (10µg, i.t.) – induced hyperalgesia in both male and female mice (A - D). The
area under the curve (AUC, 1-48h) further illustrates the effect of AC1 gene deletion on
LY2456302- (10 µg) induced reinstatement of mechanical hypersensitivity in the
ipsilateral hindpaw (D). (n = 6-15 per group)  p < 0.05 WT compared to AC1-/- mutant.
 p < 0.05 LY2456302 compared to vehicle. # p < 0.05 WT LY2456302 compared to AC1
LY2456302.  p<0.05 WT LY compared to WT vehicle, AC1 vehicle and AC1
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LY2456302. Bonferroni’s post-hoc tests followed repeated measures of 2-way ANOVA.
Data represented as mean +/- SEM.
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Next, we used a selective inhibitor of AC1, NB001 (1.5µg, i.t.) (Wang et al., 2011;
Corder et al., 2013). We performed plantar incision and assessed mechanical
hypersensitivity two days later. In 21d post-incisional mice (PIM) mice, we preadministered NB001 15 minutes before LY2456302 (10µg, i.t.). Consistent with our
previous studies, spinal delivery of LY2456302 elicited reinstatement of mechanical
hypersensitivity at 2h and 3h time points (p=0.003 and p=0.001 respectively, Figure 4.3A).
In agreement with the AC1 KO study, NB001 abolished the reinstatement precipitated by
LY2456302 (F (15, 135) = 4.00; p<0.0001, Figure 4.3A). This further illustrated by
integrated analysis over 1-2h timepoints after the drug administration (drug effect, F (1, 6)
= 21.89; p = 0.003, Table 4.3, Figure 4.3B).
To test the hypothesis that AC1 contributes to latent sensitization of dorsal horn
neurons, we evaluated the effect of AC1 deletion on a measure of neuronal activation in
the dorsal horn, phosphorylated extracellular signal-regulated kinase (pERK). We
administered LY2456302 (10 µg) intrathecally, and 2h later, at the peak of hyperalgesia,
we performed light touch stimulation in the hindpaw of WT and AC1-/- mice. We found
that the number of stimulus-evoked pERK+ profiles was significantly reduced in AC1 KO
as compared to WT mice in the ipsilateral dorsal horn (laminae I-V) (F (1, 28) = 14.35,
p=0.0007, Figure 4.4I) in both superficial (laminae I-II) and deep dorsal horn (laminae IIIV) (F (1, 56) = 11.10, p<0.0001, Figure 4.4J). As illustrated in Figure 4.4K – L, AC1
deletion decrease of nociceptive activation occurs in the ipsilateral dorsal horn laminae IV of females (F (1, 12) = 16.33, p<0.0001, fig. 4.4.K) and superficial dorsal horn of either
sex (effect of group F (3, 24) = 7.26, p=0.01, Table 4.3, Figure 4.4.L).
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Figure 4.3. Pharmacological inhibition of AC1 prevented LY2456302-induced
reinstatement of postoperative hyperalgesia.
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male
C57Bl/6 mice. (A) Pre-administration of the AC1 inhibitor NB001 (1.5µg, i.t.) prevented
LY2456302 (10µg) – induced reinstatement of hyperalgesia in both male and female mice.
(B) The area under the curve (AUC) further illustrates that LY induced reinstatement in
both sexes (n= 3-8 per group).  p < 0.05 LY compared to vehicle. # p < 0.05 NB001 +
LY2456302 compared to Vehicle + LY2456302. BL = baseline behavior prior to drug
administration. Bonferroni’s post-hoc tests following repeated measures of 2-way
ANOVA. Data represented as mean +/- SEM.
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Figure 4.4. AC1 gene deletion prevented LY2456302 - induced reinstatement of
neuronal activity in the dorsal horn.
Representative images of pERK immunoreactivity in the dorsal horn of female (A-D), and
male (E-H) mice. (A, E) LY2456302 (10 µg, i.t.) enhanced the number of pERK+ cell
profiles in WT mice in the ipsilateral side (A, E) as compared to the contralateral side (B,
F). In contrast to WT, few pERK-positive cells were observed in AC1-/- mice ipsilateral
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paw (C, G) compared to contralateral (D, H). (I - J) Histograms illustrate that LY2456302
i.t. administration increased the number of pERK+ cells in WT compared to AC1-/- male
and female mice. Images were taken with a 10X objective. n = 8 per group/4 per sex. Data
represent mean +/- SEM. ★ p<0.05. Bonferroni’s post-hoc tests following 2-way ANOVA.
Scale bars: 100μm.
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4.4.3 PKA activation reinstates behavioral signs of postoperative hyperalgesia
in male but not female mice
Recent evidence from our laboratory suggests that the cAMP receptors, PKA and
Epac1 and Epac2, are activated after nerve injury and intraplantar CFA in male rodents (Fu
et al., 2019). Our findings indicate that LS is driven by pronociceptive AC1 signaling in
the dorsal horn in both male and female mice. Therefore, we hypothesized that AC1
signaling recruits both PKA and Epac downstream signaling.
We recently reported that intrathecal administration of the selective cAMP analog
6-bnz-cAMP (6-bnz, 10nmol) reinstated mechanical when tested in male mice that
received intraplantar CFA 21 days earlier (Fu et al., 2019), but this study was restricted to
male mice. As illustrated in Figure 4.5A, 6-bnz reinstated hyperalgesia in 21d PIM mice
(F (6,156) =3.93, p=0.001). The 3-way ANOVA analyses revealed significant effects of
sex, drug and time (p=0.04, p=0.04 and p<0.0001 respectively, Table 4.4). When the data
were stratified by sex, we found that 6-bnz reinstated mechanical hypersensitivity 21d PIM
male mice (RM Two-way ANOVA, drug effect F (2, 24) =8.84, p=0.01 and drug and time
interaction F (6, 72) =3.58, p=0.003, Table 4.2, Figure 4.5B), and showed no effect in
female mice (RM Two-way ANOVA, drug effect F (2, 25) =0.58, p=0.56 and drug and
time interaction F (6, 75) =1.03, p=0.041, Table 4.2, Figure 4.5C). As illustrated in Figure
4.5D integrated analysis over time revealed the effects of sex (F (1, 33) = 5.30, p=0.02)
and drug (F (1, 33) =9.29, p=0.004, Table 4.3) on 6-bnz induced-reinstatement of
mechanical hypersensitivity (p=0.01 and p>0.99 for males and females respectively).

98

Figure 4.5. PKA activation reinstates behavioral signs of postoperative hyperalgesia
in male but not female mice.
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male
and female C57Bl/6 mice. Intrathecal administration of (A) PKA activator, 6-bnz
(10nmol), reinstated mechanical hyperalgesia in 21day post-operative but not sham mice.
Reinstatement was elicited in (B) male, but remarkably not (C) female mice. n = 9-18. (D)
The area under the curve (AUC, 0.5-1h) further illustrates the effect of sex on 6-bnz
(10nmol) driven mechanical hypersensitivity in the ipsilateral hindpaw. ★p < 0.05 6-bnz
vs. vehicle or sham. Data represented as mean +/- SEM. Bonferroni’s post-hoc tests
following ordinary or repeated measures of 2-way ANOVA.
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Next, we tested the hypothesis that PKA is necessary for the LS that is masked by
KOR. To answer this question, we pre-administered H-89 (10nmol, i.t.), a selective
inhibitor of PKA, 15 min prior to LY2456302 (10µg) delivery. Figure 4.6 illustrates that
PKA inhibition by H89 prevented LY2456302-induced hyperalgesia (drug vs. time
interaction, F (18,264) = 6.73, p<0.001, Table 4.2, Figure 4.6A) in 21PIM mice.
Corroborating with our previous data, H-89, but not the vehicle, prevented LY2456302induced reinstatement of hyperalgesia exclusively in male mice (drug vs. time interaction;
F (18,120) = 2.76, p=0.001, Table 4.2, Figure 4.6B), which is further illustrated by the
AUC (1-3h) analysis (drug vs. time interaction, F (18, 120) = 4.99, p<0.0001 for males and
p=0.69 for females Bonferroni multiple comparisons, Table 4.3, Figure 4.6D). Together
these results suggest that PKA contributes to postoperative LS in males, but not females.
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Figure 4.6. PKA inhibition prevents the reinstatement of KOR antagonist-induced
postoperative hyperalgesia in male mice.
(A)

Pre-administration of H89 (10nmol) prevented LY2456302 (LY, 10µg)-induced

reinstatement of mechanical hypersensitivity in 21-day postoperative mice. However,
when the results were stratified by sex, PKA inhibition reversed LY2456302 -induce
reinstatement (B) only in male, (C) but not female mice. (D) The area under the curve
(AUC) further illustrates that LY2456302 induced reinstatement in both sexes, but H89
prevented LY2456302 reinstatement only in male mice. n= 6-12. ★ p < 0.05 vehicle +
LY2456302 vs. vehicle + vehicle. # p<0.05 H89 + LY2456302 vs. vehicle + LY2456302.
∆ p<0.05 VHC + LY2456302 vs. H89 + VHC. Data represented as mean +/- SEM.
Bonferroni’s post-hoc tests followed repeated measures 2-way ANOVA.
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4.4.4 Epacs activation reinstates behavioral signs of postoperative
hyperalgesia in male and female mice
Cumulative evidence indicates that Epacs are required for the development of
persistent hyperalgesia after inflammation or tissue injury (Wang et al., 2013; Gu et al.,
2016; Singhmar et al., 2016; Matsuda et al., 2017; Singhmar et al., 2018) and LS (Fu et al.,
2019) . Thus, we proposed that Epacs signaling drives LS that is masked by spinal KOR
activity. To test whether Epacs mediates the pronociceptive effects of LS, we i.t.
administered the Epac selective activator 8-CPT at a dose (3nmol) previously determined
in our laboratory (Fu et al., 2019). Figure 4.7A illustrates that 8-CPT precipitated
mechanical hyperalgesia in both male and female 21 d PIM mice (drug vs time interaction,
F (6, 99) =5.27, p<0.0001, Table 4.2). Three-way ANOVA revealed significant effects of
8-CPT (p=0.01, Table 4.4) in 21d PIM mice. Subsequent two-way ANOVA analyses
shown 8-CPT effects in both sexes (drug vs time interaction, F (6, 54) =3.01, p=0.01, F (6,
45) =3.60, p=0.005, for males and females respectively), but not sham controls (Figures
4.7.B-C). As illustrated in Figure 4.7.D AUC (0.5-1h) analysis revealed the significant
effects of 8-CPT (F (6, 45) = 3.60, p=0.005, Table 4.3) on the reinstatement of mechanical
hypersensitivity in male and female mice. These data demonstrated that Epac signaling
promotes persistent postoperative latent hyperalgesia in rodents that is under inhibitory
control of KOR tonic signaling.
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Figure 4.7. Epacs drives postoperative latent sensitization in male and female mice
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male
and female C57Bl/6 mice. We used the EPAC activator, 8-CPT, to determine whether
surgical incision sensitizes EPAC signaling. (A) Intrathecal administration of 8-CPT
(3nmol) reinstated mechanical hypersensitivity three weeks after surgical incision in (B)
male and (C) female mice. (D) The area under the curve (AUC, 0.5-1h) further illustrates
the effects of sex on (8-CPT 3nmol) on mechanical hypersensitivity in the ipsilateral
hindpaw. n = 6-12 per group. Data represent mean +/- SEM. ★ p < 0.05 8-CPT vs. vehicle
or sham. Data represented as mean +/- SEM. Bonferroni’s post-hoc tests following
ordinary or repeated measures of 2-way ANOVA.
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4.4.5 Prolonged kappa opioid receptor signaling silences behavioral signs of
postoperative LS via Epacs in male and female mice
Lastly, we investigated whether KOR-masked LS is driven by the AC1 downstream
proteins Epac1-2. We performed behavior pharmacological experiments using a nonselective Epac inhibitor ESI-09 (10µg) (Almahariq et al., 2013) delivered intrathecally
15min prior to LY456302 (10µg) i.t. administration in 21d PIM mice. We found that ESI09 administration prevented the mechanical hyperalgesia induced by LY2456302 (drug vs.
time interaction, F (18, 264) =5.13, p<0.001, Figure 4.8A) in both male (drug vs. time
interaction, F (18, 120) =3.99, p=0.0005, Figure 4.8B) and female mice (drug vs. time
interaction, F (18, 120) =2.21, p=0.05, Figure 4.8C). The effects of ESI-09 on
LY2456302-induced reinstatement of hyperalgesia are further illustrated at the AUC (12h) analysis (Table 4.3, Figure 4.8D). Together, our findings indicate that Epac1-2 is a
mutual contributor to latent postoperative hyperalgesia in male and female mice. Moreover,
AC1-cAMP-Epac–dependent LS is silenced by endogenous KOR long-lasting signaling.
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Figure 4.8. Pharmacological inhibition of Epac1-2 prevents the reinstatement of KOR
antagonist-induced postoperative hyperalgesia.
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male
and female C57Bl/6 mice. We pre-administered the non-selective EPAC inhibitor ESI-09
before LY2456302. Intrathecal administration of ESI-09 (10µg) prevented LY2456302induced mechanical hyperalgesia in 21day post-operative mice (A). This was true in both
(B) male mice, and (C) female mice. (D) The area under the curve (AUC, 1-2h) illustrates
the effects of ESI-09 (10µm) on LY2456302-induced reinstatement of mechanical
hypersensitivity on both sexes. n = 6-12 per group.  p< 0.05 LY2456302 compared to
vehicle. # p < 0.05 LY2456302 + vehicle compared to ESI-09 + LY2456302 represented
as mean +/- SEM. Bonferroni’s post-hoc tests following measures of 2-way ANOVA.
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4.5 Discussion
4.5.1 Latent sensitization is driven by AC1 signaling in the dorsal horn
As a Gi/o receptor, KOR activation promotes analgesia via adenylyl cyclase
signaling inhibition (Chen et al., 1993; Bruchas and Chavkin, 2010). Similar to MOR
signaling, withdrawal from chronic administration of KOR agonists leads to AC1
superactivation (Avidor-Reiss et al., 1995; Avidor-Reiss et al., 1997). AC1 is a key
modulator of pain-related neuronal plasticity (Zhuo, 2012), as it links NMDAR activation
to pronociceptive cAMP signaling effectors increasing susceptibility to chronic pain
(Taylor and Corder, 2014). In addition, selective blockade of NMDAR precludes Nor-BNI
-precipitated hyperalgesia after recovery of postsurgical pain (Campillo et al., 2011),
indicating a role of NMDAR in postoperative LS. Thus, we hypothesized that KOR tonic
activity silences postoperative hyperalgesia via inhibition of AC1 pronociceptive signaling,
impeding the development of persistent postsurgical pain.
We found that genetic deletion of AC1 attenuates the degree of postoperative
hyperalgesia, accelerates the recovery of baseline thresholds in males and reverses
LY2456302-induced reinstatement of mechanical hypersensitivity on postoperative day 21
in both sexes. Similarly, pharmacological inhibition of AC1 prevents KOR-antagonist
mediated hyperalgesia.

Moreover, spinal nociceptive transmission induced by KOR

blockade was markedly reduced in AC1KO mice compared to WT littermates.
Collectively, our results indicate that AC1 is necessary for the development of latent
postsurgical hyperalgesia. These results are in agreement with previous studies that suggest
that AC1 is required for the establishment of pain-related sensitization (Xu et al., 2008a;
Yamanaka et al., 2017) and modulates inflammatory and persistent pain states, (Wei et al.,
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2002; Wang et al., 2011; Corder et al., 2013), including the latent inflammatory pain that
is masked by MORCA (Corder et al., 2013).
It is well accepted that AC1 is required for the induction of spinal LTP (Wang and
Zhuo, 2002; Wang et al., 2011). KOR pharmacological blockade notably reduced but did
not erase spinal nociceptive transmission assessed by pERK expression in the dorsal horn
of AC1 mutant mice. Other AC isoforms besides AC1 may also contribute to LS. It is
conceivable that AC1 gene deletion leads to a compensatory upregulation of different AC
isoforms such as its calcium-calmodulin counterpart AC-8 (Wei et al., 2006). This is in
agreement with previous studies showing that AC-8 contributes to a lesser extent to LTP
(Xia and Storm, 1997) and the development of inflammatory pain (Wei et al., 2002).
Despite a possible effect of AC8, our findings collectively support the notion that AC1 is
the critical regulator of LS. Together, our data strongly suggest that AC1 is required for
persistent nociceptive sensitization within the spinal nociceptive circuits. Therefore, we
propose that prolonged spinal KOR activity negatively regulates AC1 pronociceptive
pathways after surgery, which in part, keeps LS within a state of remission.
4.5.2 Sex differences in the latent sensitization is driven by a PKA-dependent
pathway: PKA-mediated LS in females but not males
The canonical cAMP-PKA pathway is critically involved in the development
(Taiwo et al., 1989; Malmberg et al., 1997; Yajima et al., 2003) and maintenance of
hyperalgesia after inflammatory injury (Sluka, 1997; Aley and Levine, 1999; Aley et al.,
2000; Tumati et al., 2011), or prolonged opioid exposure (Tumati et al., 2011; Araldi et al.,
2015; Chen et al., 2018b). Recent data from our laboratory demonstrates that prolonged
PKA activation also participates in the pain-related sensitization (LS) associated with
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persistent inflammation and nerve injury (Fu et al., 2019). However, these studies focused
exclusively on males. Therefore, we assessed whether PKA persistent activity also
contributes to postoperative latent sensitization masked by KOR signaling on both sexes.
Strikingly, we found that PKA activation failed to reinstate mechanical
hypersensitivity in female mice three weeks after paw incision. In addition, we
demonstrated that PKA inhibition using H-89 reversed the pronociceptive effects of
LY2456302 only in injured male, but not female mice. These results imply that there are
important sex differences in the cellular mechanisms underlying LS. To the best of our
knowledge, we are the first to evaluate the direct contribution of PKA signaling in
persistent postoperative pain. Our observations, however, are in agreement with findings
in different chronic pain models. For example, a recent study conducted in female mice
suggests that the development of hyperalgesic priming (LS) and consolidation of chronic
musculoskeletal pain require the activation of the PKC-ERK pathway in the spinal cord,
but is independent of PKA signaling (Chen et al., 2018c).
One possible mechanism for the lack of sensitivity to PKA in females after injury
is the negative regulation of PKA by estrogen. Levine and colleagues found that in contrast
to males, epinephrine-induced hyperalgesia in the spinal cord is independent of protein
kinases activity in normally cycling or gonadectomized females receiving hormonal
replacement. However, PKA signaling was restored in ovariectomized animals (Dina et al.,
2001). Conversely, an in vitro study revealed that membrane estrogen receptors regulates
ERK phosphorylation, but do not influence PKA activity (Nag and Mokha, 2014).
Our findings indicate that postoperative spinal sensitization is independent of PKA
signaling in female mice, although, these results should be interpreted with caution. First,
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the doses used in our studies were based on dose-response curves established in
pharmacological studies in male mice. Therefore, the pharmacokinetics of these drugs
might differ between male and female mice. Second, although we failed to demonstrate the
contribution of PKA in the remission phase of LS, we cannot exclude the participation of
cAMP-PKA signaling in the induction of acute postoperative pain. Recent evidence
indicates that PKA is required for the induction of hippocampal LTP in females, but not
male mice (Jain et al., 2019). Similarly, PKA activity in nociceptors is required in acute
and persistent inflammatory models in females (Aley and Levine, 1999; Araldi et al.,
2015). Thus, it is conceivable that as inflammation remits and spinal nociceptive plasticity
persists, there is a shift from a PKA dependent to a PKA-independent mechanism
associated with the activation of distinct signaling pathways. For example, a studies in
female mice showed that inflammation alters G-protein-coupled receptor kinase 2 (GRK2)
protein levels in the spinal cord and leads to cross talk of GRK2 with Epac and ERK
signaling, independently of PKA leading to persistent hyperalgesia (Eijkelkamp et al.,
2010; Huang and Gu, 2017). Alternatively, the activation of parallel cAMP pathways may
be sufficient to produce persistent hyperalgesia after surgery in females.
4.5.3 Contribution of Epacs to latent postoperative pain
We found that Epac activation by 8-CPT-cAMP (Rehmann et al., 2003) restores
mechanical hypersensitivity at least 21 days after surgery in both male and female mice.
We speculate that similar to AC1 (Corder et al., 2013), tissue injury leads to superactivation
of Epacs. This would fit with previous observations that Epac1 and Epac2 expression are
markedly increased 14 days after surgical incision in the DRG and dorsal horn in a subset
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of small non-peptidergic fibers (Cao et al., 2016; Matsuda et al., 2017), although expression
does not equal Epac activity, and Epac activity was not measured in these studies.
We found that the Epac1-2 inhibitor ESI-09 prevented the ability of LY2456302 to
reinstate hyperalgesia, indicating that Epac is required for the maintenance of LS. Our
findings are in agreement with a previous study demonstrating that ESI-09 prevents
hyperalgesia induced by the administration of inflammatory mediators 14 days after
surgical incision, but did not affect acute postoperative pain (Matsuda et al., 2017). The
effects of Epac in persistent postsurgical hyperalgesia in these studies were mediated by
p38MAPK (Matsuda et al., 2017) and lead to the translocation of PKC in primary afferents
(Hucho et al., 2005), suggesting the contribution of PKC in LS. Moreover, the activation
of specific PKC isoforms by Epac signaling was recently demonstrated in vitro (Goode
and Molliver, 2019). However, the role of downstream effectors of Epac in LS remains to
be determined.
Collectively our data indicate significant sex differences in latent postoperative
pain. We propose that an AC1-cAMP-PKA mechanism drives LS in males, while AC1cAMP–Epac signaling is a common mechanism underlying LS in both males and females.
Both pathways are kept under remission by sustained KOR activation.
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CHAPTER 5 – Final Discussion, Conclusions, and Future Directions
5.1 General Discussion
In this dissertation we aimed to investigate the contribution of opioid receptor
subtypes to postoperative latent sensitization and cellular mechanisms that drive LS in male
and female mice. Our findings indicate that spinal MOR and KOR, but not DOR mask LS.
Furthermore, our data indicate that surgical incision activates AC1, PKA, and Epac pain
facilitatory processes, which in turn, is opposed by a long-lasting spinal KOR inhibitory
signaling. One of our main findings is that spinal KOR activity differentially regulates LS
in male and female mice. Moreover, cAMP dependent pathways drive postoperative LS in
a sex-dependent manner. These findings have important implications for the development
of new therapeutics targeting postsurgical pain.
5.1.1 Kappa opioid system: paradoxical effects in pain modulation
The contribution of the KOR-dynorphin system in pain modulation has been extensively
investigated in rodents and human subjects in the past decades. According to the site of
action in the pain neuroaxis, KOR agonism result in analgesia or hyperalgesia. For
instance, peripheral restricted (Snyder et al., 2018), and KOR agonists injected into the
RVM (Hurley and Hammond, 2000; Schepers et al., 2008a) promote analgesia after injury;
while KOR activation in the central amygdala leads to hyperalgesia in primed animals (Xie
et al., 2017).
At the spinal cord level, dynorphin peptide administration leads to analgesia in
several models of acute pain, an effect that is mediated by coupling to KOR (Spampinato
and Candeletti, 1985; Podvin et al., 2016). In contrast, in chronic inflammatory and nerve
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injury models dynorphin elicits hyperalgesia/allodynia via non-opioid pathways, possibly
through direct or indirect interaction with NMDA or bradykinin receptors (Vanderah et al.,
1996; Tan-No et al., 2002; Lai et al., 2006; Luo et al., 2008). Our results demonstrated that
blockade of spinal KOR with long- or shorter-acting selective compounds during LS
reinstates hyperalgesia over one year after surgical incision, which is accompanied by
increased nociceptive spinal transmission. Thus, we provided compelling evidence that
spinal KOR signaling elicits a long-lasting postoperative endogenous antinociceptive
effect. Therefore, it is reasonable to speculate that spinal KOR masks nociceptive
sensitization in the dorsal horn after surgery through increased constitutive activity or
dynorphin-independent signaling. This hypothesis was not tested in this dissertation;
however, it is in agreement with the study of Walwyn and colleagues that showed that longacting KOR antagonists produce hyperalgesic effects at similar magnitude on 21-day CFA
WT and pre-prodynorphin deficient mice (Walwyn et al., 2016). In this line of thought,
systemic administration of the KOR antagonist Nor-BNI reinstates mechanical
hyperalgesia in surgical incised and opioid-treated mice with no evidence of changes in
spinal dynorphin levels (Campillo et al., 2010). Moreover, constitutive activity of KOR
was recently demonstrated in vivo in a preclinical model of stress-induced drug relapse.
Collectively, our results suggest that not only MORCA but also by long-lasting KOR
signaling may preclude the transition from acute to chronic postoperative pain.
5.1.1.1 Kappa opioid receptors as a potential therapeutic target for chronic
pain and addiction
The “holy grail” of opioid pharmacology is the development of opioids devoid of
the potentially fatal, and undesirable addictive effects of MOR. KOR is an attractive target
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since its activation does not elicit MOR-related adverse effects such as respiratory
depression, nausea, constipation, and has lower abuse potential (Chavkin, 2011). While
euphoria results exclusively from MOR activation in the mesocorticolimbic system, KOR
activation in the brain generates dysphoria and psychotomimetic effects (White and Roth,
2012). Thus, despite the robust postoperative analgesic effects of full KOR agonists
(Pande et al., 1996a), the psychotomimetic effects in therapeutic dosages had refrained
these drugs from further use in the clinical setting (Pfeiffer et al., 1986).
Therefore, in the field of KOR therapeutics, efforts have been concentrated in the
identification of new compounds that work through selective signaling pathways (bias
agonism) independent of β-arrestin and MAPK pathways entailed to the aversive effects
of kappa (Land et al., 2008; Chavkin, 2011).

To date, these compounds were tested

predominantly in vitro (White et al., 2015; Schattauer et al., 2017). Future studies in vivo
may shed some light on the analgesic efficacy of those compounds. Emerging research
have focused on the peripheral analgesic properties of KOR as potential treatment for
visceral pain (Stein et al., 2009; Snyder et al., 2018), however the clinical applicability of
these drugs has been contested as at higher doses peripheral restricted agonists can still
cross the blood brain barrier and elicit similar CNS adverse effects (Nielsen et al., 2015;
Naser and Kuner, 2018).
Alternatively, KOR antagonists have been proposed as potential treatment for
nociplastic disorders triggered by stress, such as migraines (Xie et al., 2017). As
previously discussed, Nor-BNI and other long-lasting KOR antagonists due to its extended
duration of action and likely cumulative effects are unsuitable for clinical use. The shortacting drugs used at the abovementioned studies are at early stages of development and
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have been tested so far only in preclinical studies. The results of these studies, however,
are very preliminary, due to the paucity of translational models of chronic stress.
Moreover, stress is only one of the initiator factors and comorbidities of these chronic pain
conditions and are not easily identified clinically. One of the KOR antagonists used in this
dissertation LY2456302 (currently known as CERC501) is currently in phase II clinical
trials for major depression. Despite the uncertainty of short KOR antagonists to manage
chronic pain, they may represent a good adjuvant or monotherapy for the treatment of
post-traumatic stress and substance use disorders (Rogala et al., 2012; Reed et al., 2018).
5.1.2 Postoperative latent sensitization may be silenced by synergism of the
opioidergic and other GPCR systems
In this dissertation, we demonstrated that LS is maintained quiescent by the longlasting activity of MOR and KOR after surgery. Our laboratory previously demonstrated
that MOR increased constitutive activity (MORCA) after injury that persistently represses
hyperalgesia (Corder et al., 2013). However, LS is also opposed by non-opioidergic
receptor systems. For example, blockade of NPY-Y1R reinstates mechanical and thermal
hyperalgesia in 21-day mice that received intraplantar CFA and 28 days after nerve injury
(Solway et al., 2011; Fu et al., 2019). Remarkably, pharmacological blockade of Y1R,
MOR and KOR reinstates hyperalgesia in a similar magnitude. These observations raised
the question of whether NPY and opioid systems act in concert through a synergistic or
additive effect. Ongoing studies in our laboratory indicate endogenous synergism between
these two receptor systems (dos Santos et al., unpublished findings), however, whether
they are co-expressed in the same population of dorsal neurons remains to be determined.
Functional interaction between GPCR has implications in pharmacology. For example,
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the formation of homo and heterodimerization between GPCR has been described
primarily in vitro, but still controversial (Al-Hasani and Bruchas, 2011). A recent study
evaluated the co-expression of MOR and DOR in vivo (Wang et al., 2018). An intriguing
hypothesis is that injury increases the formation of pain modulatory receptors systems
heterodimers to potentiate inhibitory signals and to combat pronociceptive effects during
LS.
5.1.2.1 Tonic cannabinoid receptor-1 and cannabinoid receptor -2 activity
suppresses postoperative hyperalgesia
Endocannabinoid receptor systems are implicating in the modulation of
postsurgical pain (Alkaitis et al., 2010). Similar to MOR and KOR, we found that CB1
and CB2 receptors blockade reinstates mechanical hypersensitivity in a dose-dependent
manner three weeks after surgical incision (data not shown), but in a lesser magnitude.
We then investigate whether CB1 receptors exert their analgesic effects after surgery via
constitutive activity. We found that the neutral antagonist AM4113 failed to reverse the
hyperalgesic effects of the inverse agonist rimonabant in the dorsal horn. Our results
suggest that CB1 is activated by their endogenous ligand after surgery to modulate
postsurgical hyperalgesia. Functional interactions between CB1 and KOR has been
described. Moreover, activation of CB1 and MOR heterodimers markedly reduced ERK
signaling compared to the individual activation of these receptors

(Al-Hasani and

Bruchas, 2011). Thus, it is possible that MOR and/or KOR and CB1 act in synergism to
modulate LS after surgical incision.
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Figure 5.1. Spinal administration of CB1 inverse agonist reinstates mechanical
hypersensitivity in surgical incised mice.
Mechanical thresholds at baseline (BL), 2 days, and 21 days after plantar incision in male
C57Bl/6 mice. The inverse agonist Rimonabant (30µg, i.t.) induced reinstatement of
hyperalgesia (n= 6-7 per group) in male mice effect that was not abolished by the preadministration of the neutral antagonist AM 4113 in either 1mg/kg (i.p.) (B) or 10mg/kg
(i.p.) dose.  p < 0.05 vehicle + Rimonabant compared to vehicle + vehicle. Bonferroni’s
post-hoc tests following repeated measures of 2-way ANOVA. Data represented as mean
+/- SEM.
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5.1.3 Sex differences in Latent Sensitization
In this dissertation, we explored the effects of spinal KOR signaling following
surgical incision in a preclinical model of postoperative pain. Our results demonstrated
that KOR prolonged signaling within the spinal nociceptive system promotes
postoperative endogenous analgesia in rodents. As previously emphasized, KOR agonists
were previously tested for postoperative pain in the clinical setting with limited analgesic
efficacy due to its narrow therapeutic window (Pfeiffer et al., 1986). Interestingly enough,
selective KOR agonists and mixed-action partial agonists were more efficacious
postoperatively in women and female rodents (Gear et al., 1996a; Gear et al., 1996b;
Pande et al., 1996a). These findings substantiate our observations that endogenous KOR
signaling are more pronounced in female mice after surgery. Sex differences in opioid
analgesia is attributed to gonadal hormones regulation of spinal KOR expression and
signaling, and genetic predisposition.
A remarkable finding in our studies is that c-AMP dependent signaling after surgery
differs between sexes. In females, LS is driven by a PKA independent pathway, while
AC1-Epac is a common mechanism in both males and females. One possibility is that
gonadal hormones negatively regulate PKA in females. Alternatively, it is conceivable
that cAMP-PKA signaling is present in the first stages of the development of postoperative
hyperalgesia, and as hyperalgesia progresses a shift from PKA to other pathways (i.e.
Epac) occurs due to the influence of other kinases. Nevertheless, the investigation of
differences in pain signaling pathways is important to determine possible mechanisms
associated with the higher predisposition of females to develop chronic pain, and sexspecific therapeutic targets.
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5.1.4 AC1 and Epac are potential therapeutic strategies for the management
of chronic postoperative pain
Our data and previous studies in our laboratory indicate that AC1 and Epac are
required in the transition from acute to persistent pain states in rodents. AC1 and Epac
superactivation are common mechanisms in LS opposed by opioid and other receptor
systems (Corder et al., 2013) (Fu W et al., in revision), and are observed in both male and
female mice. The window of activation of these proteins after surgery, however; remains
unclear. An interesting feature of postoperative pain is the presence of a clear etiology that
allows the distinction between acute pain and the progression to persistent pain states,
which is a challenge of most chronic pain conditions. AC1 is an interesting candidate as
its inhibition not only promotes analgesia but also combats opioid dependence. Moreover,
AC1 is highly expressed in the brain and contributes to the regulation of synaptic
plasticity, learning, and memory. Thus, a certain degree of cognitive impairment is an
expected adverse effect in future clinical trials. The development of drugs targeting AC1
downstream targets, i.e., Epac protein may circumvent these limitations.
Moreover, current studies in our laboratory conducted by Dr. Liping Zhang also
demonstrate that systemic administration of the Epac inhibitor, ESI-09, reduces
mechanical hypersensitivity and ongoing pain in a preclinical model of chronic
neuropathic pain. These observations reinforce the analgesic potential of Epacs and their
indication for the management of chronic pain. In summary, our studies indicate that
pharmacological AC1 and Epac inhibitors silence postoperative LS. Therefore, drugs
targeting AC1 and Epacs may represent good alternatives to manage chronic postoperative
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pain, avoiding the prolonged use of opioids and their deleterious side effects such as
tolerance, dependence, and addiction.
5.2 Conclusions
In this dissertation, we employed a preclinical model of chronic postoperative pain
that is ideally suited to assess candidate-signaling molecules involved in the maintenance
of pain-related plasticity and the receptor systems involved in postoperative latent pain
sensitization (LS). We demonstrated that pharmacological blockade of KOR (or MOR)
markedly restores mechanical hypersensitivity and spinal sensitization at least three weeks
after surgical intervention. Furthermore, KOR antagonism reveals a silent, persistent
sensitization mediated by AC1 and downstream cAMP-dependent signaling pathways.
Figure 5.2 summarizes this work.
Our work also indicates that surgical incision promotes long-lasting MOR and
KOR endogenous analgesia in the dorsal horn of the spinal cord that persists for at least
one year after injury. We reasoned that long-term KOR activation represses a prolonged
AC1 – cAMP – PKA and/or AC1- cAMP - Epac spinal pronociceptive signaling which,
in part, maintains LS within a state of remission. Thus, our observations suggest that any
disruption of spinal MORCA or KOR signaling, i.e., caused by significant stressful events
or additional injury, may potentiate LS pronociceptive signals leading to persistent
postoperative pain. Therefore, we propose that spinal KOR activation precludes the
transition from acute to chronic postoperative pain via inhibition of AC1 and cAMPdependent pathways.
We further extended the literature assessing the influence of biological sex on LS.
We provided evidence of a small magnitude, but significant sex difference in endogenous
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KOR-mediated postoperative analgesia. Our data suggests that females possess enhanced
spinal KOR signaling after tissue injury, which may explain, at least in part, the observed
sexual dimorphism in the responsiveness to KOR agonists administered postoperatively
in clinical trials (Gear et al., 1996a; Gear et al., 1996b; Pande et al., 1996b; Pande et al.,
1996a). Intriguingly, this work further demonstrates a sexual dimorphism in the c-AMP
dependent pathways involved in the induction and maintenance of pain-related plasticity
following surgical intervention, wherein male both AC1-cAMP-PKA and AC1- cAMPEpac drive LS, while in females LS is driven by AC1-cAMP-Epac, i.e., a PKAindependent mechanism. Moreover, selective AC1 and Epac inhibitors reverse the
reinstatement of mechanical hypersensitivity induced by KOR antagonist in both male
and female mice while PKA selective inhibition precludes LY2456302-reinstatement of
mechanical allodynia only in male mice, confirming that both AC1-cAMP pathways are
under the inhibitory control of KOR signaling. Our observations raise the prospect that
differences in signaling pathways modulating spinal nociceptive plasticity may help to
explain the higher susceptibility of females to develop chronic postoperative pain.
We present Epac as a new potential therapeutic target to manage chronic
postoperative pain, and AC1 inhibitors as a possible effective treatment for postoperative
pain. As noted, AC1 inhibition accelerates the recovery from postoperative pain in males,
and the effects of AC1 inhibition are more noticeable as hyperalgesia persists. Therefore,
the identification of sex-specific therapeutic targets should be taken into account as new
therapeutics progress into clinical trials.
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Figure 5.2. A conceptual model of pronociceptive signaling pathways suppressed by
endogenous KOR long-lasting activity in the dorsal horn following surgery in male
and female mice.
Arrows indicate activation; Line Bottom indicates inhibition; Blue Arrow indicates future
directions. For abbreviation, please see appendix 1.
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5.3 Future Directions
1. In chapter 3, our behavioral pharmacological experiments revealed that KOR signaling
maintains LS within a state of remission after surgical incision. Both Nor-BNI and
LY2456302 dose-dependently (in a M - M range) reinstated mechanical hypersensitivity
at postoperative day 21. In vitro and in vivo studies show that Nor-BNI has a slow onset
(hours –systemically (Munro et al., 2012); 30 minutes i.c.v. (Horan et al., 1992), and
transient MOR signaling effects during the first hours of action. A recent animal and
clinical studies also indicated that higher doses of LY2456302 might have off-target effects
at MOR (Reed et al., 2018). To date, the literature had evaluated the systemic effects of
LY. For the best of our knowledge, we are the first to assess the i.t. effects of this
compound. Thus, despite the low dosages used in our studies, future experiments using
KOR KO mice would help to further ratify our findings. Alternatively, selective deletion
of spinal KOR (i.e.) using dynorphin-saporin i.t. administration before plantar incision
could also be used. Moreover, behavioral pharmacological trials testing whether
LY2456302 or Nor BNI at 1 - 10µg dose reverts the effects of equi-antinociceptive i.t.
doses of MOR agonists, i.e. morphine or DAMGO, after surgical incision can also help to
confirm the selectively of KOR signaling in our studies.
2. We found that spinal MOR and KOR blockade reinstates hyperalgesia, however; we
cannot exclude pre-synaptic effects of these receptors. Indeed, recent data based on
conditional MOR KO (MOR flox/Nav 1.8 mice) mice indicates that MORs located on
central terminals of primary afferent neurons exert inhibitory effects during the remission
phase of LS (Severino et al., 2018). Similarly, a recent elegant study from the Ross group
characterized KOR expression and function on primary afferents. They showed that KOR
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expressed at peripheral and central terminals of peptidergic neurons are involved in the
control of mechanical postoperative pain (Snyder et al., 2018). Therefore, future studies
using in situ hybridization, KOR conditional KO (Cai et al., 2016) or chemogenetic
approaches may clarify the precise population of spinal KOR-expressing neurons
responsible for the endogenous control of persistent postoperative pain.
3. We tested only one or two dosages of DOR selective antagonist on figure 3.2 since
higher doses of these drugs (i.e TIPP(Ψ) 20ug, and Naltrindole10ug) elicited side effects
such as scratching, biting of back and paws, spontaneous flinching of the paws, tachypnea,
excessive grooming and jumping that prevented further testing. Moreover, we tested the
effect of Tipp (Ψ) 10ug i.t. on a separate cohort of 21-day postoperative female mice (data
not shown) and observed similar effects to the male mice (lack of reinstatement of
hyperalgesia). Taking into account possible pharmacokinetic differences of the drugs in
male and female animals, future studies using higher doses of selective DOR antagonists
in females and DOR KO mice may be beneficial to support the lack of effect of DOR
activity in LS found in our studies and rule out a possible sex dimorphism in DORmediated LS.
4. We evaluated sex differences exclusively in stimulus-evoked (mechanical) pain. Spinal
KOR neurons play a major role in the modulation of thermal pain (Martin et al., 2003;
Snyder et al., 2018), therefore; dose-response studies and studies evaluating sex differences
in thermal hypersensitivity (i.e., Hargreaves’ method (Hargreaves et al., 1988) are
warranted. In addition, the sex differences reported in postoperative pain in clinical studies
were based on patients’ self-report. Thus, potential sex differences can also be assessed
using preclinical assessment of ongoing pain (i.e., CPP or CPA) or facial expression as a
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surrogate for the visual analog scale used in the clinical trials. Furthermore, investigations
of the effects of KOR antagonists in supraspinal sites involved in pain modulation such as
the RVM (Ossipov et al., 2014) on 21 day postoperative mice should clarify whether the
discrete sex differences observed in our studies are due to spinal or supraspinal KOR
modulation of LS.
5. As gonadal hormones positively regulate the expression and function of KOR (Harris et
al., 2004; Chartoff and Mavrikaki, 2015), the outcomes observed in our studies may be
influenced by the phase of the estrous cycle in female subjects. Therefore, a major
limitation in our sex difference studies is that we did not assess the effect of gonadal
hormones in postoperative nociceptive behaviors. Future studies should evaluate the
behavioral effects of KOR antagonists in different stages of the estrous cycle using vaginal
smear in regularly cycling females after surgery. Since, pain may affect the regular estrous
cycle in females, hormone replacement studies may be also be conducted in
gonadectomized animals. In addition to hormonal studies, the effect of sex chromosomes
on KOR endogenous analgesia can also be investigated. Sex chromosome genes (XX vs
XY) in the nociceptive pathways seem to induce changes in nociception and may be
independent of gonadal hormones (Gioiosa et al., 2008). For example, XX mice present
higher brain levels of prodynorphin mRNA in the brain compared to XY irrespective of
sex (Chen et al., 2009). In addition, KOR agonists increase hot plate thresholds in neonatal
XX mice (Gioiosa et al., 2008). Thus, sex differences in KOR/dynorphin system may also
be attributable to sex chromosome complements, regardless of hormone levels.
6. The sex differences in KOR-inhibited LS may also be explained by differences in KOR
density or dynorphin levels between males and females. We have not measured KOR
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expression in the dorsal horn of the spinal cord after plantar incision. Recent data from our
laboratory (experiments performed by Mei Lu) showed that the levels of Oprk1 (KOR
gene) in the lumbar dorsal horn are significantly higher in naïve and three days after sciatic
nerve injury (SNI) in female mice. Moreover, KOR gene expression significantly changes
throughout the course of neuropathic pain development (up to 14 days after SNI) in
females. Thus, it is reasonable to speculate that KOR expression can also differ between
sexes after inflammation. KOR expression levels could be assessed in the ipsilateral vs.
contralateral L3-L4 dorsal horn at baseline and different timepoints after plantar incision
and POD-21 in male and female mice using qPCR and in situ hybridization.
7. In chapter 4, our data showed that KOR activation promotes a very long-lasting
postoperative analgesia. However, the mechanisms by which KOR signaling is activated
after surgery and LS stages remain unclear. Levels of dynorphin are reported to be
increased after surgical incision (Campillo et al., 2010). Interestingly, dynorphin deletion
does not reverse selective-KOR blockade induced-pain reinstatement after intraplantar
CFA injection (Walwyn et al., 2016). Thus, one possibility is that injury leads to KOR
constitutive activation. Recent reports reveal that reinstatement of drug-seeking is
mediated by KOR constitutive activity in the brain following acute stress (Polter et al.,
2017). However, little is known about the mechanisms that initiate constitutive signaling.
In vitro and in vivo data indicate that agonist induced-KOR activation leads to the
phosphorylation of Ser 369 residue at the KOR C-terminus tail (McLaughlin et al., 2004).
Thus, constitutive activity could be assessed using validated KOR phospho-selective
antibodies (Lemos et al., 2011) in WT and pro-dynorphin KO mice at different time points
after surgical incision using IHC or western blots. Alternatively, pharmacological
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behavioral or radioligand binding studies using i.e., Nor-BNI (KOR inverse-agonist) and
6--naltrexol as KOR (non-selective) neutral antagonist (Wang et al., 2007; Polter et al.,
2017), can be used to test the GTP-dependent binding capacity and the ability of KOR
inverse-agonist to reinstate behavioral hyperalgesia in the presence of the neutral
antagonist.
8. Our behavioral pharmacological studies indicate that AC1 and downstream cAMP
pathways drive LS and are inhibited by KOR signaling. Similar to MOR, chronic
administration of KOR agonists leads to upregulation of AC and cAMP overproduction
(Avidor-Reiss et al., 1995; Avidor-Reiss et al., 1996; Avidor-Reiss et al., 1997). Therefore,
as previously demonstrated in the MOR systems (Taylor and Corder, 2014), KOR longlasting signaling during postoperative LS may reduce AC1 super activation (cAMP
overshoot). Thus, the next logical step is to measure cAMP levels after surgical incision.
First, we could assess levels of cAMP in the lumbar spinal cord to test whether KOR
antagonist i.t. administration leads to cAMP overshoot in 21-day postoperative mice
compared to controls. As previously described, cAMP Elisa analyses can be performed in
lumbar sections of both groups (Corder et al., 2013).
9. Our results demonstrated that AC1 significantly contributed to LS, which is inhibited in
part, by KOR signaling. Although, it is conceivable that to a lesser extent, other AC
isoforms, i.e., the Ca+2-calmodulin-dependent AC, isoform – 8 (AC8) also contributes to
the induction of LS after surgery, and development of hyperalgesia in females. This
hypothesis is supported by a recent study in vitro that suggests that NB001 acts primarily
through attenuation of cAMP accumulation rather than AC1 direct inhibition (Brand et al.,
2013). Also, our pERK experiment showed that KOR blockade markedly reduced, but did
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not eliminate spinal nociceptive transmission. Thus, behavioral pharmacological and
electrophysiological studies using AC8-/-, and/or AC1/AC8 double KO can be used to
elucidate whether AC8 also participates in the induction and/or maintenance of LS. The
newly developed AC1-selective inhibitor ST034307 may also be used in future studies
(Brust et al., 2017).
10. We did not test in this dissertation whether KOR suppresses a NMDAR (NMDAR
subtypes) – AC1 pathway. Recent data from our laboratory indicates that NMDAR are
involved in the maintenance of LS unmasked by the non-selective opioid antagonist NTX.
Accumulating evidence suggest that AMPA-derived calcium is the predominant postsynaptic mechanism implicated in post-incisional sensitization (Pogatzki-Zahn et al.,
2017), and possibly also activates Ca2+ - sensitive adenylyl cyclases. Studies recently
published by our laboratory indicate the contribution of AMPARs to induction and
maintenance of LS 21 days after intraplantar CFA (Taylor et al., 2019). Therefore,
multidisciplinary studies including the administration of AMPAR/NMDAR selective
inhibitors in vivo or ex vivo, calcium imaging and biochemical approaches may help to
answer whether KOR inhibits an AMPAR and/or NMDA dependent plasticity after
surgery.
11. Our behavioral data indicate that persistent postoperative pain is mediated by cAMPPKA signaling only in male mice. The lack of effect of PKA activation or inhibition in
mechanical hypersensitivity in females may reflect the negative regulation of PKA gonadal
hormones (Dina et al., 2001). We did not control for the female estrous cycle. Thus, it will
be interesting if future studies evaluate the effect of PKA activation in 21-day postoperative
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ovariectomized mice and ovariectomized animals receiving estrogen supplementation to
rule out the influence of estrogen on PKA signaling in our studies.
12. Our behavioral studies suggest sexual dimorphism in cAMP-dependent pathways
mediating LS. Thus, biochemical measures of EPAC (i.e., western blots or in situ
hybridization) and PKA (activity assay and/or western blots) would confirm their
contribution and sexual dimorphism in LS. Moreover, these studies will help to determine
the expression and window of activation of these signaling molecules in the dorsal horn
after injury. As PKA activates several downstream substrates such as ERK 1/2 (Kawasaki et
al., 2004) and CREB (Hoeger-Bement and Sluka, 2003), it is reasonable to speculate that
i.t. delivery of the PKA activator (6-bnz) in 21-day postoperative mice would show
significant differences in the expression of these central sensitization markers in the dorsal
horn of male compared to female mice.
13. We did not determine the specific Epac isoform involved in LS, in part, due to the lack
of a selective Epac1 inhibitor. To date, only Epac 2 selective inhibitors (HJC0350) are
commercially available. Alternatively, the contribution of both Epac isoforms can be
evaluated using Epac1 and Epac 2 KO mice or siRNA approaches (Cao et al., 2016).
Furthermore, Epac is upstream of PKC (Hucho et al., 2005; Gu et al., 2016). PKC has a
central role in the induction and maintenance of spinal nociceptive plasticity (Aley et al.,
2000; Dina et al., 2001). Similar to PKA, PKC also phosphorylates ERK, CREB and
glutamatergic receptors. Thus, PKC is an interesting next step in the cAMP pathway to be
investigated in LS. We reason that similar to Epac, PKC activation is required for LS
maintenance in both sexes.
Copyright © Lilian Custodio 2019
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APPENDICES
APPENDIX 1. Abbreviations
6Bnz

N6 - Benzoyladenosine- 3', 5'- cyclic monophosphate sodium salt,
cAMP analog/PKA activator

8cpt

8-(4-Chlorophenylthio)-2'-O-methyladenosine 3', 5’-cyclic
monophosphate sodium salt, cAMP analog/EPAC activator

AC

Adenylyl cyclase

AC1

Adenylyl cyclase type 1

AC8

Adenylyl cyclase type 8

AMPA

alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid

ANOVA

Analysis of variance

AUC

Area under the curve

BL

Baseline, mechanical thresholds

CaMKII

Ca2+/calmodulin-dependent kinase II

cAMP

adenosine 3′,5′-cyclic monophosphate

CB1

Cannabinoid receptor subtype 1

CB2

Cannabinoid receptor subtype 2

CFA

Complete Freund’s adjuvant

CNS

Central nervous system

CPP

Conditioned place preference

CREB

cAMP response element binding protein

CTOP

Phe-Cys-Tyr-Trp-Orn-Thr-Pen-Thr-NH2, MOR selective
antagonist
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DAMGO

[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin, MOR agonist

DPDPE

([D-Pen2, D-Pen5] enkephalin), DOR agonist

DAPI

4', 6-diamidino-2-phenylindole

DRG

Dorsal root ganglia

DOR

Delta opioid receptor

EC50

Half-maximal effective concentration

EMAX

Maximum possible effect

Epac

Exchange protein directly activated by cAMP

ERK

Extracellular-signal-regulated kinases

GABA

Gamma-aminobutyric acid

CGRP

Calcitonin gene-related peptide

GDP

Guanosine diphosphate

GFAP

Glial fibrillary acidic protein

GIRK

G-protein linked inward rectifying potassium channel

GPCR

G-protein coupled receptor

GRK2

G-protein-coupled receptor kinase 2

GTP

Guanosine-5'-triphosphate

IASP

International Association for the Study of Pain

IB4

Isolectin B4

Iba-1

Iba-1 ionized calcium-binding adapter molecule -1e

i.c.v.

Intracerebroventricular

i.p.

Intraperitoneal

i.t.

Intrathecal
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KOR

Kappa Opioid Receptor

LS

Latent sensitization/ Latent pain sensitization

LTP

Long-term potentiation

LY

LY2456302, KOR selective antagonist

MAPK

Mitogen-activated protein kinase

MOR

Mu opioid receptor

MORCA

Mu opioid receptor constitutive activity

MPE

Maximum Possible Effect

NeuN

Neuronal nuclei

NK1R

Neurokinin receptor 1

NMDA

N-methyl-D-aspartate

Nor-BNI

Norbinaltorphimine dihydrochloride, KOR selective antagonist

NTX

Naltrexone, opioid receptor non-selective antagonist

PAG

Periaqueductal gray

PB

Phosphate buffer

PBN

Parabrachial nucleus

PBS

Phosphate buffered saline

PCR

Polymerase chain reaction

pERK

Phosphorylated extracellular-signal-regulated kinases

PIM

Plantar Incision Model

PKA

Protein kinase A

PKC

Protein kinase C

RVM

Rostral ventral medulla
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SP

Substance P

TIPPψ

H-Tyr-TicΨ[CH2-NH]Phe-Phe-OH

vF

von Frey filaments

VGCC

Voltage gated calcium channel

VGLUT

Vesicular glutamate transporter

WDR

Wide dynamic range neuron
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APPENDIX 2. IASP Taxonomy – Pain nomenclature used in this dissertation
Term

Definition

Allodynia

Pain due to a stimulus that does not normally provoke pain.

Analgesia

Absence of pain in response to stimulation which would normally
be painful.

Central

Increased responsiveness of nociceptive neurons in the central

sensitization

nervous system to their normal or subthreshold afferent input.

Hyperalgesia

Increased pain from a stimulus that normally provokes pain.

Neuropathic pain

Pain caused by a lesion or disease of the somatosensory nervous
system.

Neuropathy

A disturbance of function or pathological change in a nerve: in one
nerve, mononeuropathy; in several nerves, mononeuropathy
multiplex; if diffuse and bilateral, and polyneuropathy.

Nociception

The neural process of encoding noxious stimuli.

Nociceptive

A central or peripheral neuron of the somatosensory nervous

neuron

system that is capable of encoding noxious stimuli.

Nociceptive pain

Pain that arises from actual or threatened damage to non-neural
tissue and is due to the activation of nociceptors.

Nociceptive

An actually or potentially tissue-damaging event transduced and

stimulus

encoded by nociceptors.

134

Nociceptor

A high-threshold sensory receptor of the peripheral somatosensory
nervous system that is capable of transducing and encoding noxious
stimuli.

Nociplastic pain

Pain that arises from altered nociception despite no clear evidence
of actual or threatened tissue damage causing the activation of
peripheral nociceptors or evidence for disease or lesion of the
somatosensory system causing the pain.

Noxious stimulus

A stimulus that is damaging or threatens damage to normal tissues.

Pain

An unpleasant sensory and emotional experience associated with
actual or potential tissue damage or described in terms of such
damage.

Peripheral

Increased responsiveness and reduced threshold of nociceptive

sensitization

neurons in the periphery to the stimulation of their receptive fields.
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